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INTRODUCTION  
The Siddha system of medicine mainly practiced in the Southern part of India is 
one of the earliest traditional medicine systems in the world and deals with physical, 
psychological, social and spiritual well being of an individual. Siddha system of medicine 
is the most primitive medical system. It doesn‟t consider treatment and prevention 
separately. The main aim of this system is prevention of disease. 
As per Siddha system the man kind is inseparable from the universe. 
  
“«ñ¼ò¾¢ÖûÇ§¾ À¢ñ¼õ 
                 À¢ñ¼ò¾¢ÖûÇ§¾ «ñ¼õ” 
 
Siddhars explained the body as a whole is made up of five elements Earth, water, 
fire, air, and  Ether which are the foundamentals of creation, protection, and destruction. 
The diagnosis of disease in Siddha system of medicine relies on the Eight way 
examination methods (Envagai thervu), Naadi, Sparisam, Niram, Mozhi, Vizhi, Malam, 
Moothiram, which are evaluated in terms of the three humors. The drugs for treating 
disease have been procured from the plants, animal, and mineral origin. Various type of 
medicinal  preparations such as gruels, powder, decoctions, medicated ghee, oil, thailam, 
paste etc, are given vively. Such prepared drugs have the properties and qualities 
pertaining to panchabhootham.  
 
 The human body is conditioned by three humors consisting of Vatham, Pitham, 
Kabam. These three vital forces (Vaatham, Pitham, Kabam) of cosmic elements are 
named under the action or reaction of the panchaboothams.The deranging of this vital 
force causes disease. Aim of this system of medicine is to balance the vital forces and 
setting the right the equilibrium of the three energies. 
 
Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö ¦ºöÔõ Ñ§Ä¡÷ 
ÅÇ¢Ó¾Ä¡ ±ñ½¢Â ãýÚ 
 
In the Siddha classic Siddha Maruthuvam Pothu, Azhal keel vaayu is described as 
one amon 10 types of Keel vayu with reference in Sababathi kaiyaedu , among 10 types 
of  Keel vayu. Azhal keel vaayu is defined as a condition with symptoms of pain, 
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swelling, and stiffness in the knee joint, decrease in mobility of the knee, creaking, 
crackly sound that is heard when the knee moves, and it may be correlated to symptoms 
of Osteoarthritis in modern science. Various Siddha formulation has been mention in 
Siddha literature to treat Osteoarthritis. 
 
Osteoarthritis is a joint inflammation that results from cartilage degeneration. OA 
can be caused by aging, heredity, and injury from trauma or disease. The most common 
symptoms of pin, swollen joints, stiffness, joint creaking, loss of range of movements.  
 
Osteoarthritis is the most common form of arthritis, affecting about 237 million 
people. Among those over 60 years old, about 10% of males and 18% of females are 
affected. It becomes more common in both sexes as people become older. 
 
Patients diagnosed with Osteoarthritis visiting Ayothidoss Pandithar Hospital 
considerably increasing for the past few years. There are many treatment modalities 
available in modern system especially with Non steroidal anti-inflammatory (NSAID) 
drugs, steroids to treat Azhal keelvayu . Due to more adverse effects of these drugs the 
patients were suffering more than cure . So author decided to find a new formulation for 
this ailment. 
 
I investigator had selected “Kandathri Chooranam” (Internal) and “Erandai 
thylam” (External) for treating Azhal keelvayu (Osteoarthritis), Which is a poly herbal 
preparation to equalize the de-ranged Vaatham, Pitham and Kabam. The ingredient of the 
trail drug , Cuminum cyminum, Abies spectabilis, Syzygium aromaticum, Embelia ribes 
possess  Anti - inflammatory, Anti – oxidant property, Aanalgesic property. Hence this 
trail drug has been selected for treating Azhal Keel Vayu (Osteoarthritis). 
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AIM  AND OBJECTIVE 
To evaluate the therapeutic efficacy of Siddha herbal formulation of “Kandathiri 
chooranam” (Internal) and “Erandai Thailam” (External)  for “Azhal KeelVayu” 
(OsteoArthritis of Knee joint) with and without Varmam. 
 
OBJECTIVE:   
 
PRIMARY OBJECTIVE:   
 
To evaluate the therapeutic efficacy of Siddha drugs “Kandathiri 
Chooranam”(Internal) and “Erandai Thailam” (External) in reducing the pain and 
restricted joint movements in the treatment of “Azhal Keel Vayu” (Osteoarthritis) 
through comparative clinical study. 
 
SECONDARY OBJECTIVE:   
1.To study the Siddha basic principles like Envagai thervu, Kaalam, Udal Thaathu etc. 
2.To Study the effect of Varmam in Azhal Keel Vayu patients along with trail drug. 
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REVIEW OF LITERATURE 
SIDDHA ASPECT OF AZHAL KEEL VAYU 
 
Siddha system of Medicine is an ancient one enriched with good resources. The 
sources of Siddha medicines include Herbs, Minerals, Metals and also animal origin. 
 
The system not only deals with medicinal but with spirituality, righteous way of 
living, Rejuvenation and its main aim is attainment of perfection.  
 
The universe around as in the Macrocosm (Andam) and the human body is 
considered as the Microcosm (Pindam). Any changes in the Macrocosm will have its 
impact in the Microcosm in the human body. 
 
"¿¢Äó¾£ ¿£÷ÅÇ¢ Å¢Íõ§À¡¨¼óÐõ 
 ¸Äó¾ ÁÂì¸õ ¯Ä¸õ ¬¾Ä¢ý 
 þÕ¾¢¨É ³õÀ¡ø þÂ¦ÉÈ¢ ÅÆ¡ «¨Áò 
 ¾¢Ã¢Å¢ø ¦º¡ø¦Ä¡Î ¾Æ¡«ø §ÅñÎõ." 
¦¾¡ø¸¡ôÀ¢Âõ ¦À¡Õû «¸Ã¡¾¢. 
 
The poet explains that both Andam and Pindam formed by the basic five elements called 
panchaboodhams. They are 
 
1. Pirithivi (Earth) 
2. Appu (Water)  
3. Theyu (Fire 
4. Vaayu (Air) 
5. Aahayam (Ether) 
These five elements combined to form Three Thathus.  
1. Vaatham 
2. Pitham  
3. Kabam 
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"¾Äí¸¡ðÊ þó¾î º¼Á¡É ¨ÅõÀâ¾õ 
¿¢Äí¸¡ðÊ ¿£÷¸¡ðÊ ¿¢ýÈ¢Îó ¾£ ¸¡ðÊ 
ÅÄí¸¡ðÊ Å¡ÔÅ¡ø ÅÇ÷§¾ þÕó¾ 
   ÌÄí¸¡ðÊ Å¡É¢ü ÌÊÂ¡ Â¢Õó¾§¾" 
   "þÕó¾¢Î Á¢ù¨Åóò ¦ÄÎò¾ º¼Á¢Ð" 
 
(¾¢Õãø÷ ¿¡Ê) 
 
These three thathu composed of  
1. Vatham = Air + Ether 
2. Pitham = Fire  
3. Kabam = Earth + water 
 
The physiological units of the Human body is otherwise called as Vali (Vatham), 
Azhal (Pitham), Iyyam (Kabam). They are also formed by the combination of the five 
basic elements. Accordingly Vali is formed by the combination of Vayu (Air) and 
Aagayam (Space). This is the Creative force. Azhal is formed by theyu (Fire). This is the 
Force of Preservation. Iyyam is formed by Prithivi (Earth) and Appu (Water). This is the 
Force of Protection. These three humors are in the ratio of 4:2:1 in equilibrium which is a 
healthy normal condition and disturbance in their equilibrium leads to diseases. This is 
denoted in 
  "¦À¡í¸¢Â£¨ÃóÐìÌð ¦À¡øÄ¡ ãýÚ ¾¡ý 
  ¾í¸¢ÂÅ¡Ôî ºÁ÷ò¾ý Á¸¡Å¾õ 
  Àí¸¢ÂÅýÉ¢Â¡÷ ÀÌó¾Ð À¢ò¾§Á" 
  "ÀÌó¾ ºÄò¾¢ü ÀÃ¢º¢ìÌõ ¿ø¸¨ÄÂõ 
  ÅÌó¾þõ ãýÈ¡ø ÅÇ÷¾Ð §¿¡¦ÂøÄõ" 
  (À¾¢¦½ý º¢ò¾÷ ¿¡Ê º¡ò¾¢Ãõ) 
 
These three thathus perceived as Naadi which is unique feature of Siddha 
system.When the above three humours are affected (or) not in a balanced state , they 
become Kuttram which predisposes to diseases.  
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I.Vali (Vaatham) 
These active elements are always supported by the two stable elements, for 
change can only happen upon the foundation of stable. Thus Vayu and Aahaayam 
combine to become “Vaatham humor” which controls all aspects of movements as well as 
space with in the body. In spite of this combination, however, Vaatham sends to primarily 
display the characteristics of Vayu-Air. The words “Dry, light, cold, quick, rough, minute 
and mobile” describes the characteristics of Vaatham. 
 
II.Azhal (Pitham) 
 This is the function that governs all the body‟s conversion processes as well as its 
heat and energy producing capacities. Pitham is primarily characterized by the qualities of 
Theyu, which are “ hot, sharp, penetrating, light, acidic, and slightly oily ”. 
 
III. Iyyam(Kabam): 
 It controls liquefaction, lubrication and cohesion. It is also responsible for giving 
solidity and structure to the body. Kabam primarily reflects the qualities of the water, but 
also some traits of the earth elements, consequently, Kabam is heavy, slow, cold, steady, 
solid and oily. 
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ARTHRITIS – KEEL VAYU 
 Arthritis is a group of conditions involving damage to the joint of the body. There 
are over 100 different forms of arthritis. Excess of vaatham affects the joints all over the 
body and Vitiation of Kabam causes indigestion. Thus the end product of digestion 
associated with vaatham, pitham, kabam blocks the tissue pores and passages with waxy 
material. It also affects simultaneously the joints of the body such as knee, shoulder, hip, 
neck etc. This produces the pain, swellon of the joints. Hence it is also known as 
“AZHAL  KEEL VAYU”. 
 
AZHAL KEEL VAYU : 
In  Siddha  literature Azhal keel vayu described under keel vayu . Then the keel vayu 
is the general term that includes all kind of joint disorders. 
Azhal keel vaayu is defined as increase in vaatham and pithakutram, characterised by pain 
in joints, swelling, tenderness, caused by various causes as mentioned below. 
 
TYPES OF KEEL VAYU 
There are ten types of KeelVayu which are mentioned in the text “Siddha 
Maruthuvam Pothu”. Azhal Keelvayu is one among 10 types of Keel Vayu. 
 
The 10 types are mentioned below 
1.Vali Keel Vayu 
2.Azhal Keel Vayu 
3.IyyaKeel Vayu 
4.Vali Azhal Keel Vayu 
5.Vali Iyya Keel Vayu 
6.Azhal Vali Keel Vayu 
7.Azhal Iyya Keel Vayu 
8.Iyya Vali Keel Vayu 
9.Iyya Azhal Keel Vayu 
10.Mukkutra Keel Vayu 
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AETIOLOGY: 
According to Yugi Vaithya Sinthamani, 
 
±ýÉ§Å Å¡¾ó¾¡ ¦ÉñÀ ¾¡Ìõ 
Á¢Ìò¾¢§Ä ÁÉ¢¾¸÷¸Ùì ¦¸öÐ Á¡Ú 
À¢ýÉ¦Å ¦À¡ó¾¨É§Â §º¡Ãï ¦ºöÐ 
¦ÀÃ¢§Â¡÷¸û À¢Ã¡Á½¨Ãò à‰ ½¢òÐõ 
ÅýÉ§ÅÅî¦º¡ò¾¢ü §º¡Ãï ¦ºöÐ 
Á¡¾¡À¢¾ ÌÕÅ ÁÈó¾ §À÷ìÌõ 
¸ýÉ§Å §Åò¨¾ ¿¢ó¨¾¦ºö¾ §À÷ìÌí 
¸¡Âò¾¢ü ¸Äó¾¢Î§Á Å¡¾ó ¾¡§É 
 
¾¡¦ÉýÈ ¸ºô§À¡Î ÐÅ÷ôÒ ¨ÃôÒ 
º¡¾¸Á¡ö Á¢ïÍ¸¢Ûï º¨Áò¾ ÅýÉõ 
¬¦ÉýÈ Å¡È¢ÉÐ ¦À¡º¢ò¾ Ä¡Öõ 
¬¸¡ò §¾ÈÄÐ ÌÊò¾ Ä¡Öõ 
À¡¦ÉýÈ À¸ÖÈì¸ Á¢Ã¡Å¢ Æ¢ôÒ 
ÀðÊÉ¢§Â Á¢¸×Ú¾ø À¡Ã ¦Áö¾ø 
§¾¦ÉýÈ ¦Á¡Æ¢Â¡ü §Áü º¢ó¨¾ Â¡¸¢ø 
º£ì¸¢ÃÁ¡ö Å¡¾ÁÐ ¦ºÉ¢ìÌó ¾¡§É 
¬½¡É ÅÃýÈý¦ÉÇ¦Â Á¾¢Â¡ Á¡ó¾÷ 
«¸¾¢ÀÃ §¾º¢Â÷¸ð ¸ýÉ Á£Â¡÷ 
§¸¡ÉÉ ÌÃ¦Á¡Æ¢¨Â ÁÈó¾ §À÷¸û 
¦¸¡¨Ä¸Ç× ¦À¡ö¸¡Áí ÌÈ¢ò¾ §À÷ìÌ 
°É¡É º¼ó¾ýÉ¢ø Å¡¾õ ÅóÐ 
¯üÀÅ¢ìÌõ §Å¾ò¾¢ Öñ¨Á ¾¡§É. 
   ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
 
 According to the saint Yugis in his work, those who are squandering money, 
insulting the elders, blaspheming the Holy books, not respecting the divine gifts, 
abandoning or forgetting the parents having wickedness in their mind and those with 
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sleeping  in the day time and awake up during night  will get Vaatham disease,  hot, taste, 
increased intake of water, excessive starvation, increased intake of  bitter and astringent 
taste, increased sexual indulgence desire will produce Vaatha disease. 
 
In the above literature saint Yugimuni said that the Vaatha diseases are 
precipitated in the months from Aani to Karthigai (June to December), hence the seasonal  
factors are involved and facilitate the Vaatha diseases. 
 
FACTORS THAT INFLUENCE THE VATHA TYPE OF DISEASES: 
¸¡Ä þÂøÒ– Environmental Factors: 
Relation between occurrence of Vaatha Diseases and Seasonal 
variations: 
  “¬ÊÂ¡¾¢Â¡ö ³ôÀº¢ ®È¡ 
  «½¢ÄÁ¾üý §¸¡ÃÃº¢Âø ¸¡Äõ.” 
 Vaatham elevates in the body from the month of Aadi to Iyppasi (July to 
September) i,e from the middle of Muthuvenil kaalam, Kaar kaalam to half of Koothir 
kaalam. 
 To summarise, Vaatha diseases occur due to certain diet capable of increasing 
vatham, certain habits and environmental changes which elevates vatham. 
 
 
Diet: 
 
 ¦¾¡Æ¢ø¦ÀÚ ¨¸ôÒì¸¡÷ò¾ø ÐÅ÷ò¾ø Å¢ïÍ¸¢Ûï 
 §º¡Õõ ¸¨ÆÂ¾¡õ ÅÃÌ Áü¨Èô¨Àó¾¢¨É ÂÕó¾¢É¡Öõ 
 ±Æ¢ø ¦ÀÈôÀÖÈí¸¢ þÃÅ¢É¢ÖÈí ¸¡¾¾¡Öõ 
 Á¨Æ ¿¢¸÷ ÌÆÄ¢É¡¦Ä Å¡¾í§¸¡ À¢ìÌí ¸¡§½. 
     - ÀÃÃ¡º §º¸Ãõ 
 
  According to Pararasa sekaram , excess consumption of  bitter taste, astringents 
and sour taste, inceased intake  of old cooked  rice, intake of grains, day time sleep and 
wake up at night time will get Vaatham diseases. 
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THE CLINICAL FEATUES OF AZHAL KEEL VAAYU IN  
SABAABATHI  KAIYEEDU : 
 À¢ò¾ì¸£ø Å¡ö× ¾ýÉ¡ü 
 À¢ÈìÌ¸£ý ãðÎ Å£í¸¢î 
 º¢ò¾÷¦ºö ÁÕòÐ ÅòÐï 
 º£÷À¼¡ò ¾ý¨Áò ¾¡¸¢ò 
 ¾ò¾Ú ¸¡öîºø ¸ñÎ 
 º¡Ä§Å  ¾¨É¾¡ý ¾ó§¾ 
 ¦Áò¾Ú º¢¸¢î¨º ¾ýÉ¡ø 
 ¦Áý§Áø ¿£íÌ ÁôÀ¡. 
     ºÀ¡À¾¢ ¨¸§ÂÎ 
 
 It is characterised  by pain, swelling and knee popping or cunching of the both 
knee joints. 
 
DIAGNOSIS: 
 “§¿¡ö¿¡Ê §¿¡öÓ¾ É¡Ê ÂÐ¾½¢ìÌõ 
    Å¡ö¿¡Ê Å¡öôÀî ¦ºÂø” 
       ¾¢ÕìÌÈû. 
 
 This Thirukural quote explains the importance of diagnosis as it is to be made in 
order of the aetiology, root of cause of the disease thereby treating the disease with 
appropriate medicine. 
 
Piniyarimuraigal (Method of Diagnosis) : 
 Piniyarimuraigal (Method of Diagnosis) is based upon the three main      
principles: 
 Poriyal Arithal(Inspection) 
 Pulanal Arithal(Palpation)  
 Vinaathal (Interrogation) 
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1.  Poriyalarithal (Inspection): 
 “Poriyalarithal” means examining the “Pori” of the patient by the physician for 
proper diagnosis. 
             Pori-five sense organs.  
             They are as follows 
 Nose 
 Tongue 
 Eye 
 Skin 
 Ear 
2. Pulanalarithal (Palpation): 
 “Pulanalarithal” means examining the “Pulan” of the patient by the       
physician to diagnosis a disease. 
Pulan- senses They are, 
 Smell 
 Taste 
 Vision 
 Sensation of touch 
 Hearing 
 
3. Vinaathal (Interrogation): 
 Vinaathal is gathering of information about the history of the disease, its clinical 
features etc., from the patient or his close relatives who are taking care of them. Vinaathal 
is helpful when the patient is not in a position to speak or when the patient is child. 
  
Types of Naadi (Pulse) felt in Azhal Keelvaayu: 
 In Siddha system of Medicine “Naadi diagnosis (Pulse reading)” is the first and 
foremost diagnostic parameter. 
 In Azhal Keel Vaayu the following types of Naadi can be commonly seen. 
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They are, 
 Vaatha pitham 
 Vaatha kabam 
 Pitha vaatham 
 Kaba vaatham 
 
 
DIFFERENTIAL DIAGNOSIS: 
NOI KANIPPU VIVATHAM (DIFFERENTIAL DIAGNOSIS): 
 Azhal Keel Vayu is differentiated from the following diseases, 
 
 VALI KEEL VAYU:  
 It is characterised by excruciating pain and swelling involving knee joints, 
hip joints, elbow joints, shoulder joints and associated with systemic disturbances 
like dryness of mouth, pyrexia, headache, palpitation, constipation and sweating. 
In advanced cases it may affect the heart . 
 IYA KEEL VAYU: 
 It is characterised by severe pain in the joints associated with emaciation 
of the body, anorexia, insomnia, cough, hiccough, vomiting, anaemia and dropsy. 
The common sites are spinal cord, hip joints and knee joints. 
 VALI IYA KEEL VAYU:  
 It is characterised by pain in the joints associated with effusions of joint 
fluid and swelling, restricted joint movements, pyrexia, fainting, insomnia, 
especially in knee joint asymmetrically, lymphadenopathy, generalized malaise, 
atrophy of the affected limb etc. The affected joint looks like “Fox‟s Head”. 
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LINE OF TREATMENT 
 In Siddha system, the treatment is based upon the Mukkutram principle. Treatment 
is not only for perfect healing but also for the Prevention of disease progression and 
Rejuvenation of  Udalkattugal. 
 While treating a disease, it is essential to know the etiology, the nature of the 
patient, severity of the illness, the seasons and the time of occurrence. 
 
LINE OF TREATMENT IS AS FOLLOWS: 
 1.Kaappu (Prevention)  
 2.Neekkam(Treatment)  
 3.Niraivu (Restoration) 
 
1.KAAPPU (PREVENTION): 
 “Prevention is better than cure” is a proverb. Knowing the cause there by 
removing it and thus preventing the disease is the main aim of Siddha system of 
medicine. 
 Siddha system emphasizes the purification of thought and activities in the 
underlying lines quoted from the text “Theraiyar Pinianuga Vithi” which emphasizes 
virtueness to be followed even in the daily life activities.i.e., 
 
 À¡Öñ§À¡õ ±ñ¦½ö¦ÀÈ¢ý ¦Åó¿£÷ ÌÇ¢ô§À¡õ 
 À¸üÒ½§Ã¡õ À¸üÚø§Å¡õ À¡§Â¡¾ÃÓ ãò¾ 
 ²Äï§º÷ ÌÆÄ¢ÂÃ§Ã¡Ê Ç¦ÅÂ¢Öõ Å¢Õõ§À¡õ; 
 þÃñ¼¼ì§¸¡õ; ´ý¨ÃÅ¢§¼¡õ; þ¼Ð¨¸Â¢ü ÀÎô§À¡õ. 
 
2.NEEKAM (TREATMENT INSIDDHA): 
The aim of treatment is based on, 
1. To bring the Three Thodams to normal equilibriumstate. 
2. To treat the patient by Internal and externalmedicines. 
3. To stabilize 7 Udalthadhukal and 3Uyirthadhukal. 
To bring the three Thodams to normal equilibrium state first by giving purgation. 
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Diet Restrictions (Pathiyam): 
 During the course of treatment, the patients were advised to follow certain dietary 
regimen (Icha pathiyam) which is mentioned for vaatha diseases. 
 
1. Kadugu 
2. Ell Nei 
3. Kalyana Poosanikkai 
4. Kadalai 
5. Thengai 
6. Mangai 
7. Poondu 
8. Pala 
9. Kollu 
10. Pugaiilai 
11. Pagal 
12. Agathi 
13. Sourtaste 
14. Astringenttaste 
 
3. NIRAIVU (RESTORATION): 
 Reassurance from disease recovery was given to all patients by promoting the awareness 
about the dietary, seasonal, emotional influence on the disease. Life-style modification was also 
advised to them. 
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MODERN ASPECTS ANATOMY OF JOINTS:  
Joints can be classified as synovial, fibrous, or combination joints, based on the 
presence or absence of a synovial membrane and the amount of motion that occurs in the 
joint. Normal synovial joints allow a significant amount of motion along their extremely 
smooth  articular surface. 
 
 The joints are composed of the following: 
 Articular cartilage 
 Subchondral bone 
 Synovial membrane 
 Synovial fluid 
 Joint capsule. 
The normal articular surface of synovial joints consists of articular cartilage 
(composed of chondrocytes) surrounded by an extracellular matrix that includes various 
macromolecules, most importantly proteoglycans and collagen. The cartilage protects the 
underlying subchondral bone by distributing large loads, maintaining low contact stresses 
and reducing friction at the joint. Synovial fluid is formed through a serum ultra filtration 
process by cells that form the synovial membrane (synoviocytes). Synovial cells also 
manufacture the major protein component of synovial fluid, hyaluronic acid (also known 
as hyaluronate). Synovial fluid supplies nutrients to the avascular articular cartilage; it 
also provides the viscosity needed to absorb shock from slow movements, as well as the 
elasticity required to absorb shock from  rapid movements. 
 
ANATOMY OF THE KNEE JOINT 
Introduction: 
The knee joint is the largest joint in the body, consisting of four bones and an 
extensive network of ligaments and muscles. Injuries to the knee joint are amongst the 
most common in sporting activities and understanding the anatomy of the joint is 
fundamental in understanding any subsequent pathology. 
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Bones of the knee joint: 
The knee is made up of four main bones. The femur (thigh bone), the tibia 
(shinbone),fibula (outer shin bone) and patella (kneecap). The main movements of the 
knee jointoccur between the femur, patella and tibia. Each are covered in articular 
cartilage which is anextremely hard, smooth substance designed to decrease   the 
frictional forces as movementsoccur between the bones. The patella lies in an indentation 
at the lower end of the femur known as the inter-condylar groove. At the outer surface of 
the tibia lies the fibula, a long thin bone that travels right down to the ankle joint. 
 
 
 
 
The capsule: 
The knee joint capsule is a thick ligamentous structure that surrounds the entire 
knee. Inside this capsule is a specialized membrane known as the synovial membrane 
which provides nourishment to all the surrounding structures. Other structures include the 
infrapatellar fat pad and bursa which function as cushions to exterior forces on the knee. 
The capsule itself is strengthened by the surrounding ligaments. 
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Ligaments of the knee joint: 
 
  
 The stability of the knee owes greatly to the presence of its ligaments. Each has a 
particular function in helping to maintain optimal knee stability in a variety of different 
positions. 
 
Menisci (knee cartilage): 
Each knee joints has two crescent shaped cartilage menisci. These lie on the 
medial and lateral edges of the upper surface of the tibia bone. They are essential 
components, acting as shock absorbers for the knee as well as allowing for correct weight 
distribution between the tibia and the femur. 
 
LIGAMENTS AND MENISCI OF KNEE JOINTS 
Two internal ligaments-the anterior and posterior cruciate ligament ligament also 
help to maintain the proper alignment of the knee. The anterior curciate ligament is the 
most anterior of these internal ligaments and extends obliquely from surface of the lateral 
condyle of the femur to the anterior intercondylar space of the tibia.  
 
The ACL plays an important role in preventing hyperextension of the knee by 
limiting the anterior movement of the tibia. Directly behind the ACL is the posterior 
cruciate ligament PCL, which extends obliquely from the inner surface of the medial 
condyle of the femur to the posterior intercondylar space of the tibia. PCL prevents the 
posterior movements of the tibia relative to the femur. 
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Muscle groups surrounding the knee joint: 
The two main muscle groups of the knee joint are the quadriceps and the 
hamstrings. Both play a vital role in moving and stabilizing the knee joint. 
  
Quadriceps muscle: 
The quadriceps muscle group is made up of four different individual muscles 
Which join together forming the quadriceps tendon. This thick tendon connects the 
muscle to the patella which in turn connects to the tibia via the patellar tendon. 
Contraction of the quadriceps, pull the patella upwards and leads to knee extension. 
 
Hamstrings muscle: 
The Hamstrings muscle function in flexing the knee joint as well as providing 
stability on either side of the joint line. 
 
OSTEO ARTHRITIS (OA) : 
 
INTRODUCTION: 
OA is a degenerative joint disease involving the cartilage and many of its 
surrounding tissues. In addition to damage and loss of articular cartilage, there is 
remodeling of sub articular bone, osteophyte formation,  ligamentous laxity, weakening 
of  periarticular muscles and in some cases, synovial inflammation. 
 
These changes may occur as a result of an imbalance in the equilibrium between 
the breakdown and repair of joint tissue. Primary symptoms of OA include joint pain, 
stiffness and limitation of  movement. Disease progression is usually slow but can 
ultimately lead to joint failure with pain and disability. Osteoarthritis is abbreviated as 
OA or referred to as degenerative arthritis or degenerative joint disease (DJD). 
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EPIDEMIOLOGY: 
International statistics:  
            The prevalence rises progressively with age and it has been estimated that 45% of 
all people develop knee OA and 25% hip OA at some point during life. Although some 
are asymptomatic, the lifetime risk of having a total hip or knee replacement for OA in 
someone aged 50 is about 11% for women and 8% for men in the UK. There are major 
ethnic difference in susceptibility : the prevalence of  hip OA is lower in Africa,China , 
Japan and the Indian Subcontinent than in European countries , and that of knee OA is 
higher.   
 
Pathophysiology: 
     OA is a complex disorder with both genetic and environmental components . Genetic 
factors are recognized as playing a key role in the pathogenesis of OA. Family –based 
studies have estimated that the heritability of OA ranges  from about 43% at the knee to 
between 60% and 65% at the hip and hand, respectively, in most cases, the inheritance is 
polygenic and mediated by several genetic variants of small effect. OA can, however, be a 
component of multiple epiphyseal dysplasias, which are caused by mutations in the genes 
that encode components of cartilage matrix .Structural abnormalities, such as slipped 
femoral epiphysis and developmental dysplasia of the hip, are also associated with a high 
risk of OA, presumably due to abnormal load distribution across the joint. Similar 
mechanisms probably explain the increased risk of OA in patients  with limb deformity 
secondary to Paget s disease of bone. Biomechanical factors play an important role in OA 
related to certain occupations, such as farmers, professional athletes .It has been 
speculated that the higher prevalence of knee OA in the Indian subcontinent and East 
Asia might be accounted for by squatting.There is also a high risk of OA in people who 
have had destabilizing injuries such as cruciate ligament rupture , and those who had 
meniscetomy. 
For most individuals, however, participation in recreational sport does not appear 
to increase the risk significantly . There is a strong association between obesity and OA, 
particularly of the hip. This is thought to be due  partly to biomechanical factors but it has 
also been speculated that cytokines released from adipose tissue may play a role. 
Oestrogen appears to play a role; lower rates of OA have been observed in women  who 
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use hormone replacement therapy , and women who receive aromatase inhibitor therapy 
for breast cancer often experience a flare in symptoms of OA. 
       OA is a complex disease whose pathogenesis includes the contribution of 
biomechanical and metabolic factors which, altering the tissue homeostasis of articular 
cartilage and subchondral bone, determine the predominance of destructive over 
productive process. A key role in the pathophysiology of articular cartilage is played by 
cell/extra cellular matrix interactions, which are medited by cell surface intergrins.In a 
physiologic setting, intergrins modulate cell/ECM singnaling, essential for regulating 
growth and differentiation and maintaining cartilage homeostasis. During OA, abnormal 
intergrins expression alters cell/ECM signaling and modifies chondrocyte synthesis, with 
the following imbalance  of destructive cytokines over regulatory factors.IL-1, TNF-alpha 
and other  pro-catabolic cytokines activate the enzymatic degradation of cartilage matrix 
and are not counterbalanced by adequate synthesis of inhibitors. The main enzyme 
involved in ECM breakdown are metalloproteinases, which are sequentially activity by an  
partially inhibited by the tissue inhibitors of MMPs, whose synthesis is low compared 
with MMP productin in OA cartilage. Intriguing is the role of growth factors such as 
TGF-beta, IFG, BMP,NGF, and others ,which do not simply repair the tissue damage 
induced by catabolic factors, but play an important role in OA pathogenesis. 
 
Symptoms of OA: 
 Pain 
 Swelling 
 Stiffness in th knee joint 
 Decrease in mobility of the knee. 
 Creaking, crackly sound that is heard when the knee moves. 
 
DEFORMITY: 
Deformity can occur with osteoarthritis due to bone growths and cartilage loss. 
Bone growths in the end joints of the fingers are called Heberden„s nodes. Bouchard„s 
nodes are bone growths in the middle joints of the fingers. Degeneration of knee cartilage 
can result in the outward curvature of knee (bow- leggedness). 
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CLASSIFICATIONS: 
It could be divided into 2 types : 
1. Primary or idiopathic osteoarthritis 
2. Secondary osteoarthritis 
  
1.Primary or idiopathic osteoarthritis: 
It is due to wear and tear changes occurring in old age in which the weight bearing 
joints like the hips and knees are more commonly affected. It is uncommon in non-weight 
bearing joints like the shoulder and elbow. Obesity is a predisposing factor. 
 
2.Secondary osteoarthritis: 
It is due to an abnormal wear and tear in a joint, caused by mechanical incongruity 
of the articular surfaces. This incongruity is due to the 
 Mal-union of fractures involving the articular surfaces of tibia, femur    orpatella 
 Loose bodies in the joint 
 Mal alignmentof the bones due to deformity like genu valgum or genu varum. 
 
 
ETIOLOGY: 
PRIMARY CAUSE OF OSTEOARTHRITIS: 
The real cause is abnormal stress and strain on the joints associated with loss of 
mucopolysaccharide content of the matrix of the articular cartilage. 
 
Though exact cause is not known, the following factors are suspected to play an 
important role in the causation of primary osteoarthritis  
 Endocrine 
 Post Traumatic 
 Inflammatory joint disease 
 Metabolic 
 Congenital or developmental 
 Genetic 
 Neuropathic and others 
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SECONDARY CAUSES OF OSTEO ARTHRITIS: 
The causes for secondary osteoarthritis of the knee are as follows:  
 Obesity 
 Rheumatoid arthritis, infection, trauma, TB, etc. 
 Hyper parathyroidism. 
 
DIFFERENCE BETWEEN NORMAL AND ARTHRITIC JOINT 
 
 
RISK FACTORS : 
 Factors that increase your risk of osteoarthritis include: 
 Older age:  
 The risk of osteoarthritis increases with age.  
 
 
 23 
 
 Bone deformities:  
 Some people are born with malformed joints or defective cartilage, which 
can increase the risk of osteoarthritis. 
 Joint injuries: 
 Injuries, such as those that occur when playing sports or from an accident, 
may increase the risk of osteoarthritis. 
 Obesity: 
 Carrying more body weight puts added stress on your weight-bearing 
joints, such as your knees. 
 
INVESTIGATIONS: 
X-Ray : 
a. Radiological features: The earliest change seen is the asymmetrical 
 narrowing of the joint space and subchondral sclerosis in the medial compartment 
 of the joint. Later, osteophytes are seen in the periphery of the articular surfaces of 
 the femur, tibia and patella. 
 
b. Arthroscopic Examination 
  It allows direct inspection and visualization of the damaged joint surface. 
 
c. Synovial fluid Analysis 
  Shows non-inflammatory picture 
 
d. Bone scan 
 
e. CT 
 
f. MRI 
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VARMAM: 
Varmam is a science dealing with the impact to innumerable nerve junctions of 
the human body. The changes occurring in the body on being hit at some specific points  
directly or indirectly with a particular force is known as Varmam. 
 
  In human body from the head to toe there are numerous varmam. 
 
Varmam is considered as one of the unique branch in Siddha system of  medicine. 
Since ancient days it has been developed and used as martial of defensive art and also 
used in medical healing practice. According to Siddha literature, Varmam therapy is 
considered as “Vital points therapy” by which the diseases are healed by manipulating 
some pressure points either by touch or massage. 
 
This Varmam points may be the nerve junctions, muscular junction or the  
points that the Pranan lived. 
 
Varmam is the vital life energy points located in human body and was  
identified as 108 points by the Siddhars. When these points are hit with a particular force 
directly or indirectly, pathological changes occur in the body. The intensity of the 
changes depends on the force of hitting that particular point, the duration exposed to the 
force and physical strength of the affected person. 
  
The effects observed when Varmam point is affected are pain, swelling, bleeding 
(at the hit site or near the corresponding natural orifice, spasm of the limbs, loss of 
function of the vital organs, vomiting, protrusion or in-drawing of the tongue, in-drawing 
or herniation of testicles, protrusion of eyeball, breathlessness, fainting and even death 
may result. 
 
The term Varmam also indicates the therapeutic manipulation of specific points in 
which the pranic energy is found concentrated. Manipulation over these points with a 
particular force for the specific time will release the pranic energy from these points and 
brings relief to the affected individual by regulating the flow of pranic energy which is 
obstructed due to assault on specific points (Varmam points) or due to other cause. 
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In our lifestyle Varmam is the major cause for muscular strain, sprain, joint pain 
and low back pain. It is present in our inner aspect of our body. So it is otherwise called a 
MARMAM. On the other hand the name Marmam mean that the point should be keep as 
secret.   
 
Varmam energy circulation (Sara ottam): 
 
 “Utaluyir nadithannil unthidum vaasiyathaam 
   Oonudal maruviye oodadum nilaiye varmam” 
 
According to Varmam Sara Nool, Human body consist of a vital energy 
circulation that passes continuously and transmits energy to the whole body. This 
ciuculation is called as ―Varma energy circulation  (Sara Ootam) and the energy that 
passes through is called as “Saram or Vaasi” 
 
Thasanadis are the vital energy channels by which the energy circulation takes 
place. The energy that passes will retained, stored and transmitted in certain areas or 
points of human body and that points are called as Varmam points or Vital points. In our 
Siddha literature Varmam is basically divided into two parts They are  
 
1. Medicinal aspect 
2. Defence & offence aspect 
 
SYNONYMS AND OTHER NAMES OFVARMAM: 
Kalam, Adakkam, Marmam, Sutcham, Vanmam, Emam, Idu , Karuvi, Kalai,  
Seevan Swasam, Puravi, etc.. 
  
Varmam–Art as well as science: 
Varmam is an art as well as a science. As an art it can be employed to attack a 
person to make a permanent or temporary disability to a person (which is normally not 
done) .It is also a science, it helps treat persons from the impact arising from traumatic 
injuries. 
 26 
 
CLASSIFICATION OF VARMAM: 
There are 2 major classification present in Varmam 
They are classified as below 
1. Padu varmam  
2. Thodu varmam  
 
VARMAM POINTS TO BE MANIPULATED IN AZHAL KEEL 
VAYUPATIENTS:  
 Kaal Moottu Varmam 
 Komberi Varmam 
 Viruthi 
 Ullangal vellai 
 
KAAL MOOTTU VARMAM: 
Synonyms: 
 ãðÎ Å÷Áõ ( Å÷Á Ýò¾¢Ãõ-101) 
            ( ¸ñ½¡Ê-500) 
 ¸¡ø ãðÎ Å÷Áõ (Å÷Á Å¢ÃÄÇ× áø) 
 
Location: 
 “¾¡É¾¢§Ä ÓðÊ¨ºÅ¢ø ãðÎ Å÷Áõ” (Å÷Á ¸ñ½¡Ê-500) 
 Located in the popliteal fossa 
 
KOMBERI VARMAM :  
Synonyms: 
 ÐõÀ¢ì¸¡Ä Å÷Áõ (Å÷Á áÄÇ× áø) 
 ¦¸¡õ§ÀÈ¢ Å÷Áõ (Å÷Á Ýò¾¢Ãõ 101) 
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Location: 
 “²Ìõ Ó¼× þ¨ÈÃñÊø ÐõÀ¢ì¸¡Äõ” («ÊÅ÷Á Ýðºõ-500) 
 Located at the centre of the medial aspect of the leg. 
 
VIRUTHI VARMAM: 
Synonyms: 
 Å¢ü¾¢ Å÷Áõ (Å÷Á ¸ñ½¡Ê-500) 
 Å¢÷ò¾¢ Å÷Áõ («ÊÅ÷Á Ýðºõ-500) 
  
Location: 
 “§À¡¦ÁýÈ ¦ÀÕÅ¢Ãø ¦Á¡Æ¢ §Áø Å¢÷ò¾ ¸¡Äõ” («ÊÅ÷Á Ýðºõ 500) 
 Located in the space in between the great toe and second toe on the dorsum of  the 
foot. 
 
ULLANGAL VELLAIVARMAM: 
Synonyms: 
 ¦Åû¨Ç Å÷Áõ (Å÷Á ´Ê×ÓÈ¢× ºÝò¾¢Ãõ -1200) 
 «¼í¸ø Å÷Áõ (Å÷Á Ýò¾¢Ãõ 101) 
 ¯ûÇí¸¡ø Å÷Áõ ( Å÷Á Å¢ÃÄ× áø)  
 
Location: 
 “«¸Á¡É ¯ûÇõ ¸¡ø ¦Åû¨Ç Å÷Áõ” («ÊÅ÷Á Ýðºõ 500) 
 Located on the depression in between the eminences of great toe and second toe in 
the plantar aspect of the foot 
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DRUG REVIEW 
 
PROPERTIES OF TRAIL DRUG 
 
INTERNAL MEDICINE : KANDATHRI CHOORANAM 
 
    INJI 
 
Botanical name  : Zingiber officinale 
Family   : Zingiberaceae 
Parts used            :  Rhizome 
 
Organoleptic characters 
 
Taste   :  Kaarppu 
Potency  : Veppam 
Division  : Kaarppu 
 
Actions:  
    
 Carminative 
 Stomachic 
 Digestive. 
          Chemical constituents: 
 
 Gingerol 
 Paradols 
 Shogaol, 
 Glycosides, 
 Terpenoids, 
 saponins. 
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General characters : 
 
“þïº¢ì ¸¢ÆíÌì ¸¢ÕÁø µì¸¡Çõ 
 Åïº¢ìÌï ºýÉ¢ÍÃõ Åý§À¾¢ -Å¢ïÍ¸¢ýÈ 
       Ý¨ÄÂÚõ Å¡¾õ§À¡ó àñ¼¡¾ ¾£ÀÉÁ¡õ 
                     §Å¨ÄÔÚí ¸ñ§½¡ö”.  
        
      («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
 
SEERAGAM 
 
Botanical name  : Cuminum cyminum 
Family   : Apiaceae 
Parts used            :  Seed 
 
Organoleptic characters 
 
Taste   :  Kaarppu, Inippu 
Potency  : Thatppam 
Division  : Inippu 
 
Actions: 
    
 Carminative 
  Stomachic 
  Astringent. 
Chemical constituents: 
 
 Terpinene 
 Limonene 
  Safranal, 
 𝛽-pinene 
 Vitamins B and E 
 Cymene. 
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General characters : 
“§À¡ºÉ Ì¼¡Ã¢¨Âô Òº¢ì¸¢ø§¿¡ ¦ÂÄ¡ÁÚí 
 ¸¡ºÁ¢ Ã¡¾ì ¸¡Ãò¾¢ ÖñÊ¼”. 
                                            (§¾Ãý - ¦ÅñÀ¡) 
 
   MILAGU  
 
Botanical name  : Piper nigrum 
Family   : Piperaceae 
Parts used            :  Seed 
 
Organoleptic characters 
  
Taste   :  Kaippu, Kaarppu 
Potency  : Veppam 
Division  : Kaarppu 
 
Actions: 
    
 Carminative   
 Antivatha 
  Antidote 
Chemical constituents: 
 
 Piperine 
  Phellandrene 
 Linalool 
  Limonen 
  Pinen 
 
General characters : 
 
 “§¸¡Ï¸¢ýÈ Àì¸ÅÄ¢ ÌöÂ×§Ã¡ ¸õÅ¡¾ 
 §º¡½¢¾í¸ Øò¾¢üÌû §¾¡ýÚ§¿¡ö-¸¡½Ã¢Â 
 ¸¡Ð§¿¡ö Á¡¾÷ÌýÁí ¸¡Á¡¨Ä Áó¾¦ÁýÈ£÷ 
 ²Ð§¿¡ö ¸¡Â¢Õì¸¢ø ®íÌ”.   («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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    THALISAPATHIRI 
 
Botanical name  : Abies spectabilis 
Family   : Pinaceae 
Parts used            :  Dried leaves 
 
Organoleptic characters  
Taste   :  Kaarppu 
Potency  : Veppam 
Division  : Kaarppu 
 
Actions:  
 Carminative 
 Stomachic 
  Epectorant 
 
Chemical constituents: 
 Α-pinene 
  β-phellandrene 
  Tannins 
  Alkaloids 
 Steroids 
  Glycosides 
 
General characters : 
  “¿¡º¢ ¸ÇôÀ¢½¢¸û ¿¡ðÀðð-¸¡ºïÍ 
            Å¡ºõ «Õº¢ ÅÉÁí¸¡ø-Å£º¢ÅÕ 
            §Á¸Áó¾õ «ò¾¢ÍÃõ Å¢ð§¼Ìó ¾¡Ç¢ºò¾¡ø 
            ¬Ìï Í¸ôÀ¢Ãº Åõ”.            («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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THIPPILIMOOLAM 
 
Botanical name  : Piper longum 
Family   : Piperaceae 
Parts used            :  Root 
 
Organoleptic characters  
Taste   :  Kaarppu 
Potency  : Veppam 
Division  : Kaarppu 
 
Actions :    
 Stomachic. 
 
Chemical constituents: 
 Saponins 
 Ketones 
 Aldehydes 
 Phytols 
 Piperine 
  Sabinene 
  Chavicin, 
 Limonene, 
  β-caryophyllene  
 Piperyline 
 Phellandrene 
 
General characters : 
 “¾¡¸À¢ò¾ï §º¡¸ó ¾½¢Â¡î ÍÃÁ¢ÕÁø 
 §Á¸í ÌÃü¸õÁø ¦Áöì¸ÎôÒõ-²Ìí¸¡ñ 
 ¾¢ôÀ¢Ä¢ã Äí¸ñ¼ò ¾¢ôÀ¢Ä¢Â ¾¡õ¿ÚìÌò 
 ¾¢ôÀ¢Ä¢¦Âý §È¦Â¡Õì¸ü ¦ºôÒ”.  («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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KIRAMBU 
 
Botanical name  : Syzygium aromaticum 
Family   : Myrtaceae  
Parts used            :  Dried bad 
 
Organoleptic characters  
Taste   : Kaarppu    
Potency  : Veppam  
Division  : Kaarppu  
 
Actions:    
 Carminative 
  Antispasmodic 
 Stomachic 
 
Chemical constituents: 
 Carcacrol 
 Thymol 
 Eugenol 
 
 
General characters : 
 “À¢ò¾ ÁÂì¸õ §À¾¢¦Â¡Î Å¡ó¾¢Ôõ§À¡õ 
 Íò¾Å¢Ãò ¾ì¸ÎôÒó §¾¡ýÚ§Á¡-¦Áò¾ 
 þÄÅí¸í ¦¸¡ñ¼ÅÕì §¸ü Í¸Á¡Ìõ 
 ÁÄÁí§¸ ¸ðÎ¦ÁÉ Å¡úòÐ”.  («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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KOTTAM 
 
Botanical name  : Costus speciosus 
Family   : Costaceae 
Parts used            :  Root 
 
Organoleptic characters  
 
Taste   :  Kaippu 
Potency  : Veppam  
Division  : Kaarppu 
 
Actions :  
 Stomachic  
 Tonic  
 Expectorant 
Chemical constituents: 
 
 Tigogenin 
 Diosgenin 
 Tetracosanoic acid 
 Succinicacid 
  β-sitosterol  
General characters : 
 
 “¿¡ðÊÖÚ ¦Åð¨¼ ¿Îì¸õ ±Û§¿¡ö¸û 
 §¸¡ð¼¦ÁÉî ¦º¡ýÉ¡ø Ì¨ÄÔí¸¡ñ-ÜðÊü 
 ÍÃ§¾¡¼ó ¦¾¡ñ¨¼§¿¡ö §¾¡Ä¡¾ À¢ò¾õ 
 ÀÃ§¾ºõ §À¡§Á ÀÈóÐ”.  («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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VAIVILANGAM 
 
Botanical name  : Embelia ribes 
Family   : Primulaceae 
Parts used            :  Seed 
 
Organoleptic characters 
  
Taste   :  Kaippu 
Potency  : Veppam  
Division  : Kaarppu 
 
Actions : 
 
 Carminative 
  Stomachic 
 Anthelmintic . 
Chemical constituents: 
  
 Embelin 
 Christembine   
 Quercitol 
 Sitosterol  
 Tannin  
 Cinnamic acid 
 Chrorogenic acid 
 
General characters : 
 
 “À¡ñÎÌð¼õ ÌýÁõ ÀÕóàÄ §¿¡öÅ¡¾ó 
 ¾£ñÎ ¾¢Ã¢Å¢¼ï º¢ÃóÐñ¼õ-âñ¼ÁÊ 
 §¿¡öÅ¢Çí¸ì ¸¡ð¼¡¾ Ññ¸¢ÕÁ¢ Â¡ºÉôÒñ 
 Å¡ö Å¢Çí¸ì¸¡ð¼ Å¢ÕÁ¡÷”.                 («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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   SARKARAI  
 
Botanical name  :  Borassus flabellifer  
Family   : Arecaceae  
Parts used            :  Fruit 
 
Organoleptic characters  
 
Taste   :  Inippu,Thuvarppu 
Potency  :  Thatppam  
Division  :  Inippu 
  
Actions : 
 
 Nutrient 
 Diuretic 
 Astringent 
 Chemical constituents: 
 
 Albuminoids 
 Fats 
 Steroids 
 
General characters : 
 
 “.....................................................................¾íÌÀ¨É 
 ¦ÅøÄò¾¡ø Å¡¾À¢ò¾õ Å£Ú¸Àï ºýÉ¢§¿¡ö 
 ÅøÄÕº¢ ÌýÁÚ Á¡ø”. 
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EXTERNAL MEDICINE : ERANDAI THYLAM 
AMANAKKU ENNAI 
 
Botanical name  : Ricinus communis 
Family   : Euphorbiaceae 
Parts used            :  Seed 
 
Organoleptic characters 
  
Taste   :  Kaippu 
Potency  : Veppam  
Division  : Kaarppu 
 
Actions:  
 
 Anti-vatha 
  Laxative 
General characters : 
 
 “Å¡¾ò ¦¾¡¼ì¨¸ ÅÃ¦Å¡ð¼¡ ÁüÀÊìÌì 
 ¸¡¾òÐì ¸¡ôÀ¡ü ¸ÊÔ§Á-Ý¾ò¨¾ô 
 §ÀÃñ¼ô Àó¾¢ìÌõ §À¾¢ìÌ §¿¡öì¸¡ð¨¼ 
 §Â÷ñ¼ ¦ÁýÀ¾¢É¢§Â”.    («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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MILAGU 
 
Botanical name  : Piper nigrum 
Family   : Piperaceae 
Parts used            :  Seed 
 
Organoleptic characters  
 
Taste   :  Kaippu, Kaarppu 
Potency  : Veppam  
Division  : Kaarppu 
 
Actions :  
 
 Carminative  
 Anti-vatha  
 Antidote 
 
General characters : 
 
 “§¸¡Ï¸¢ýÈ Àì¸ÅÄ¢ ÌöÂ×§Ã¡ ¸õÅ¡¾ 
 §º¡½¢¾í¸ Øò¾¢üÌû §¾¡ýÚ§¿¡ö-¸¡½Ã¢Â 
 ¸¡Ð§¿¡ö Á¡¾÷ÌýÁí ¸¡Á¡¨Ä Áó¾¦ÁýÈ£÷ 
 ²Ð§¿¡ö ¸¡Â¢Õì¸¢ø ®íÌ”.   («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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VELLAI POONDU 
 
Botanical name  : Allium sativum 
Family   : Amaryllidaceae 
Parts used            :  Rhizome 
 
Organoleptic characters 
  
Taste   :  Kaarppu 
Potency  : Veppam  
Division  : Kaarppu 
 
Actions: 
  
 Carminative 
 Stomachic 
 Expectorant 
 Diuretic 
 
General characters : 
 
 “ºýÉ¢¦Â¡Î Å¡¾ó ¾¨Ä§¿¡× ¾¡ûÅÄ¢ 
 ÁýÉ¢ÅÕ ¿£÷ì§¸¡¨Å Åýº£¾õ-«ýÉ§Á 
 ¯ûÇ¢ûÇ¢ ¸ñÀ¡ö ¯¨ÇãÄ §Ã¡¸Óõ §À¡õ 
 ¦ÅûÙûÇ¢ ¾ýÉ¡ø ¦ÅÕñÎ”.   («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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MANJAL 
 
Botanical name  : Curcuma longa 
Family   : Zingiberaceae 
Parts used            :  Rhizome 
 
Organoleptic characters  
 
Taste   :  Kaarppu 
 Potency  : Veppam  
Division  : Kaarppu 
 
Actions :   
   
 Carminative 
  Hepatic tonic  
 Stimulant 
General characters : 
 
 “¦À¡ýÉ¢ÈÁ¡õ §ÁÉ¢ ÒÄÉ¡üÈ Óõ§À¡Ìõ 
 ÁýÛ ÒÕ¼ Åº¢ÂÁ¡õ-À¢ýÉ¢¦ÂØõ 
 Å¡ó¾¢À¢ò¾ §¾¡¼¨ÁÂõ Å¡¾õ§À¡ó ¾£ÀÉÁ¡í 
 Ü÷ó¾Áïº Ç¢ý¸¢ÆíÌìÌ”.  («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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KADUGU 
 
Botanical name  : Brassico juncea  
Family   : Brassicaceae 
Parts used            :  Seed 
 
Organoleptic characters 
  
Taste   :  Kaarppu 
Potency  : Veppam  
Division  : Kaarppu 
 
Actions :  
 Emetic 
 Stimulant 
 Digestive 
 Diuret 
 
General characters : 
 
 “Áó¾õÁÂì ¸õÅ¡¾õ Å¡ö¿£÷î ÍÆüÈÄÚ 
 ÓóÐ Í¸ôÀ¢Ãº Åí¸Ùñ¼¡-Á¢óÐÑ¾ý 
 Á¡§É ¸¢Ã¡½¢ÌýÁ Á¡ÚÓò ¦¾¡¼Óõ§À¡õ 
 ¾¡§É ¸Î¸¢üÌò ¾¡ý”.     («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
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KUPPAIMENI 
 
Botanical name  : Acalypha indica  
Family   : Euphorbiaceae 
Parts used            :  Leaves 
 
Organoleptic characters 
  
Taste   :  Kaippu, Kaarppu 
Potency  : Veppam  
Division  : Kaarppu 
 
Actions : 
  
 Emetic 
 Expectorant 
 Anodyne 
 Diuretic 
 Anthelmintic 
General characters : 
 
 “¾ó¾ã ÄôÀ¢½¢¾£ò ¾ó¾¢ÞÒñ º÷ÅÅ¢¼õ 
 ¯óÐÌýÁõ Å¡¾õ ¯¾¢Ãã-Äó¾¢É× 
 ÝÄïÍ Å¡ºõ ¦¾¡¼÷À£ ºí¸Àõ§À¡õ 
 »¡Äí¦¸¡û §ÁÉ¢Â¾ É¡ø”    (§¾Ãý-Ì½Å¡¸¼õ) 
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INGREDIENTS OF INTERNAL MEDICINE: 
 
KANDATHRI CHOORANAM 
 
INGI 
           
 
 
SEERAGAM 
 
 
MILAGU 
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THALISAPATHIRI 
 
 
 
THIPPILI MOOLAM 
 
 
 
 
KIRAMBU 
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KOTTAM 
 
 
 
 
VAI VILANGAM 
 
 
 
 
 
SARKKARAI 
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INGREDIENTS EXTERNAL MEDICINE: 
 
ERANDAI THYLAM 
 
AAMANAKKU ENNAI 
 
 
 
MILAGU 
 
 
 
POONDU 
 
e  
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MANJAL 
 
 
 
 
KADUGU 
 
 
 
 
KUPPAIMENI 
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MATERIALS AND METHODS 
 
To evaluate the therapeutic efficacy of Siddha herbal formulation of “Kandathiri 
chooranam”(Internal) and “Erandai Thailam”(External)  for “Azhal Keel Vayu” (Osteo 
Arthritis of Knee joint). 
 
STUDY DESIGN:  
An open clinical trial 
STUDY PLACE: 
Ayothidoss Pandithar Hospital, National Institute of Siddha, Tambaram 
sanatorium, Chennai-47 
 
DISEASE CONDITION: 
 
 Pain  
 Swelling  
 Stiffness  
 Crepitation 
 Tenderness 
 Warmth 
 Restricted movements. 
 
STUDY PERIOD: 18 months 
SAMPLE SIZE: 40 patients 
(20 patients will be treated with trail medicine; 20 patients will be treated with trail 
medicine along with Varmam therapy.) 
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DRUG FORMULATION: 
 
INTERNAL MEDICINE: 
 
Drug   :    KANDATHIRI CHOORANAM 
Reference book :   Agasthiyar Vaithiya Rathina Churukkam 
Page No  :   46 & 47 
Dosage       :   1250 -1500 mg (Verukadi)  
Adjuvant   :   Cold water 
Duration    :   48days (1 Mandalam) 
Edition   :  2
nd
 Print, Feb-1998. 
Author   :  S.T.Ramachandran 
Publication  :  Thamarai Noolagam 
 
EXTERNAL MEDICINE: 
Drug   :  ERANDAI THAILAM 
Dosage     : Q.S (for external application) 
Reference           : Saravendhira Vaithiya Muraigal 
Page no  :  12 
Edition  :  4
th
 Print, Nov-1998. 
Author   : K.Vasudheva Sasthiri 
Publication  :  Saraswathi Noolagam 
 
VARMAM POINTS TO BE APPLIED TO THE PATIENT: 
 Kaal Mootu Varmam (Varma Viralalavu Nool) 
 Komberi (Varma soothiram 101) 
 Viruthi (Varmalaada soothiram 300) 
 Ullangal Vellai (Adivarma sootcham 500)   
     
INCLUSION CRITERIA: 
 Age : 30-65 Yrs 
 Sex : Both male and female 
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 Patients having symptoms of arthritis of both knee joints, Pain, swelling, stiffness, 
crepitation, restricted movements of knee joint. 
 Patients who are willing to undergo radiological investigation, Laboratory 
investigations. 
 Patients willing to sign the informed consent stating that he/she will 
conscientiously  stick to the treatment during 48days but can opt out of the trial of 
his/her own conscious discretion. 
 
EXCLUSION CRITERIA: 
 Cardiac diseases 
 Rheumatoid arthritis 
 Pregnancy and lactation 
 Patient with any other serious systemic illness 
 Chronic kidney disease 
 Tuberculosis of knee        
 Septic arthritis        
 Gonococcal arthritis   
 H/o Diabetes mellitus 
 
WITHDRAWAL CRITERIA: 
 
 Intolerance to the drug and development of adverse reactions during drug trial. 
 Poor patient compliance and defaulters. 
 Patient turning unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness 
 
TESTS AND ASSESSMENTS:  
A. Clinical assessment  
B. Laboratory investigations 
C. Radiological investigations 
D.  Siddha system assessment. 
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B. Routine investigation 
Blood: 
 Hb 
 Total WBC Count 
 DC-  Polymorphs 
1. Lymphocytes  
2. Eosinophil  
3. Monocytes  
4. Basophils  
 Total RBC count 
 ESR 
½ Hr:                 1 Hr: 
 Blood sugar 
Fasting:               PP: 
Urine: 
 Albumin 
 Sugar 
 Deposits 
 
Renal function tests: 
 Urea 
 Creatinine 
 
Liver function tests: 
 Serum total bilirubin 
 Direct bilirubin 
 Indirect bilirubin 
 Serum Alkaline phosphatases 
 SGOT 
 SGPT 
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SPECIFIC INVESTIGATIONS: 
 CRP 
 ASO TITRE 
 RA FACTOR 
 
C. RADIOLOGICAL INVESTIGATIONS 
X- Ray Knee joints (AP and Lat view) 
 
D. SIDDHA PARAMETERS: 
Envagai thervugal: 
  Naadi 
Sparisam 
Naa 
Niram 
Mozhi 
Vizhi 
Malam 
Moothiram 
 NeerkKuri 
 Neikkuri. 
 
STANDARD OPERATIVE PROCEDURE 
Source of Trial Medicine: 
  The required raw drugs for the preparation of “Kandathiri Chooranam” (internal) 
and “Erandai Thailam” (external)will be purchased from a well reputed country shop and 
the raw drugs will be authenticated by the competent authority (medicinal botany and 
gunapadam department). After that the raw drugs will be purified separately and the 
medicine will be prepared in Gunapadam laboratory of National institute of Siddha. 
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Purification of raw drugs: 
Inji (Zingiber officinale) 
 To be outer layer removed. 
 
Seeragm (Cuminum cyminum) 
  To be dried under sunlight without any dust particle 
 
Milagu (Piper nigrum):                                                                    
 To be dired under sunlight without any dust particle. 
 
Thalisapathiri (Abie sspectabilis)  
 
 To be dired under sunlight without any dust particle. 
 
Thippili moolam (Piper longum )  
To be dry under sunlight without any dust particle. 
 
Kirambu (Syzygium aromaticum) 
   To be dried under sunlight  without any dust particle. 
 
Kottam (Costus speciosus) 
  To be dried under sunlight without any dust particle.    
 
Vai vilangam (Embelia ribes) 
  To be dried under sunlight without any dust particle.   
 
Sarkkarai (Borassus flabellifer) 
 To be clean the dust particles 
 
Reference:  
 Sikitcha Rathina Deepam ,Saraku Suthi Muraigal. 
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Method of Preparation: 
   Take ginger(10 palam)  with outer skin removed and then cut in to small pieces. 
Then soak that ginger piece in lemon juice for one day. Then dry that soaked over sun on 
next day.  
 
 Then take 1 palam of cumin and soak that in lemon juice for one day. Then dry 
that soaked cumin over sunlight on next day.  Purify and powder the below raw drugs and 
then add same amount of sugar . 
 
Inji 
 Seeragam 
Milagu 
Thalisapathiri 
Thippilimoolam 
Kirambu 
Kottam 
Vaivilangam 
 
B.External Medicine: 
Ingredients: 
 Amanakku Yennai (Ricinus communis)     -          ½ palam (17.5 gm) 
 Milagu (Piper nigrum)   -  ½ palam (17.5 gm) 
 Manjal (Curcuma longa)                              -           ½ palam (17.5 gm) 
 Kadugu (Brassiajuncea)   - ½ palam (17.5 gm) 
 Vellai poondu (Allium sativum)  - ½ palam (17.5 gm) 
 Kuppaimeni charu (Acalyphaindica)  - ½ padi (670 ml) 
 
Purification of drugs: 
Amanakku yennai (Ricinus communis) 
To be take amanakku yennai in a vessel and place that vessel in sand with 
exposure to sun. 
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Milagu (Piper nigrum):                                                                    
To soak pepper in butter milk for 1 hr 15 mins and then rost it. 
 
Vellai Poondu (Allium sativum) 
 To be remove the outer layer. 
 
Kadugu (Brassia juncea) 
 To be take the mustard in a vessel and place that vessel in sunlight for two days. 
 
Manjal (Curcuma langa) 
 To be remove the out layer and then cut into small pieces. To be dried under 
sunlight. 
 
Kuppaimenicharu (Acalypha indica) 
 To be washed with water and dry it. 
 
Reference: 
Sikitcha Rathina Deepam. 
 
Method of preparation: 
 All the above ingredients except kuppaimeni are taken in equal proportion (1/2 
palam) and powdered well and mixed.Take one vessel, Then add ½ padi of kuppaimeni 
saru and place that in sunlight and add other powdered drugs.then add aamanakku ennai 
then heat for sometime in the evening.Then it should be stored in dry container. 
 
Drug storage:     
The trial drug “Kandathiri Chooranam” is stored in clean and dry container and  
“Erandai Thylam”is stored in clean and dry narrow mouthed bottles. 
 
Dispensing: 
 The Chooranam is given in packets and oil is given in bottles. 
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OUTCOME: 
  
A. Outcome of the study will be assessed by the following:  
      1. Universal Pain assessment scale 
                  2.   Questionnaire of  Osteoarthritis : 
 
1.UNIVERSAL PAIN ASSESMENT SCALE:
 
 
  Grade   0    : No Pain 
  Grade 1 -3 :  Mild pain 
  Grade 4-6 :  Moderate pain 
         Grade 7-10 :  Severe pain   
 
OUTCOME: 
  0 : Good improvement 
  1-3 : Moderate improvement 
  4-6 : Mild improvement 
  7-10 : No improvement 
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B. Questionnaire of  Osteoarthritis : 
Name 
Age 
   
Which knee is bothering you?  
 
Right   Left    Both 
Did your knee pain start with a specific injury?  
  
Yes   No 
If yes: Date of injury:  
Mechanism of injury : 
 
 
Did you feel a pop or snap with the injury?  
 
Yes       No 
Is the injury work related? 
 
 Yes   No 
Did your pain start with a particular sport or activity? 
 
Yes   No 
If yes, what started the pain?  
 
 
If there was no injury, when did the pain start?  
 
 
What part of your knee hurts? Front Inside Outside Back 
What are your primary sports and/or activities?  
 
 
How would you describe your pain? (constant, intermittent, mild, severe, etc.) 
 
Do any of the following increase your pain? 
 
Prolonged walking: Yes  Minimally  No 
 
Prolonged standing: Yes   Minimally    No 
 
Going up or down stairs:  Yes  Minimally  No 
 
Prolonged sitting: Yes  Minimally  No 
Getting up from a sitting position:  Yes  Minimally  No 
 
Kneeling or squatting: Yes  Minimally  No 
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Pivoting or twisting motions:  Yes  Minimally  No 
 
Running:  Yes  Minimally  No 
 
Sports:  Yes  Minimally  No 
 
Is there anything else that increases your pain?  
 
Do any of the following decrease your pain? 
 
Rest:  Yes  Minimally  No 
 
Ice:  Yes  Minimally  No 
 
Heat:  Yes  Minimally  No 
 
 
Do you have any of the following symptoms? 
Weakness in your leg:  Yes  Minimally  No 
 
Giving way or buckling of your knee:  Yes  Minimally  No 
 
Locking of your knee (unable to fully straighten):  Yes  Minimally  No 
 
Clicking or catching in your knee:  Yes  Minimally  No 
 
Grinding sensation in your knee:  Yes  Minimally  No 
 
Swelling of your knee:  Yes  Minimally  No 
 
Stiffness:  Yes  Minimally  No 
 
Pain at night:  Yes  Minimally  No 
 
Numbness or tingling in your leg:  Yes  Minimally  No 
 
Are there any other symptoms that we need to know about regarding your knee? 
Have you had any prior surgery to your knee(s)?  Yes  No 
 
If yes, what type of surgery did you have and when did you have the surgery? 
 
Have you had any prior treatment for your knee pain such as: 
 
Cortisone injections:  Yes  No 
 
Synvisc, Euflexxa or “Gel” injections:  Yes  No 
 
Physical therapy:  Yes  No 
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Do you use any ambulatory aids (cane, crutches, walker)  Yes  No 
 
Have you had any x-rays taken of your knee(s):  Yes No 
 
If yes: Date of x-rays: 
 
X-ray facility 
 
Have you had an MRI of your knee(s):  Yes No 
 
If yes: Date of MRI:  
Is there anything else we need to know about your knee pain? 
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11. STUDY ENROLLMENT:  
 
Patients reporting at the OPD with the clinical symptoms of Azhal Keel Vayu will be 
examined clinically for enrolling in the study based on the inclusion and exclusion 
criteria.  
 
The patients who were enrolled would be informed (Form VI) about the study, trial 
drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them and informed consent would be obtained in writing from them in 
the consent form (Form VI).  
 
All these patients will be given unique registration card in which patients‟ 
Registration number of the study, Address, Phone number and Doctors phone number etc. 
will be given, so as to report easily should any complications arises. 
 
Complete clinical history, complaints and duration, examination findings and 
laboratory investigations -- would be recorded in the prescribed Proforma. Patients will 
be advised to take the trial drug and to follow the appropriate dietary advice. 
 
CONDUCT OF THE STUDY: 
Purgation will be given with coarse of Meganaatha Kuligai-2 with Hot water at early 
morning in empty stomach will be given for balancing the deranged mukkutram a day 
before the treatment.  
 
The trial drug Kandathiri Chooranam (Internal) and Erandai Thailam (External) are 
given continuously for 48 days.  OPD patients are requested to visit the hospital once in 
seven days.  In each and every visit clinical assessment is done and prognosis is noted in 
the Prescribed Proformas.  For In patients clinical assessment is done daily. 20 patients 
will be given Varmam treatment along with trial medicines. Laboratory investigations and 
Radiological investigation are done on the before and the last day of the trial.  Defaulters 
of will not be allowed to continue and be withdrawn from the study.  
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ETHICAL ISSUES: 
1. To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of laboratory 
equipments will be used.      
2. No other external or internal medicines will be used, other than the trial drug for 
osteoarthritis. There will be no infringement on the rights of the patient. 
3. The data collected from the patient will be kept confidential.  
4. After getting the consent of the patient only (through consent form in their own 
vernacular language) they will be enrolled in the study. 
5. Treatment would be provided free of cost. 
6. In any adverse reaction observed during the trial the patients will be given 
alternative treatment at National Institute of Siddha for further management.  
 
DATA COLLECTION FORMS:  
Required information will be collected from each patient by using the following forms: 
FORMS: 
 Form I   Screening and selection Proforma 
 Form II   History taking & Clinical assessment Proforma 
 Form III   Laboratory investigation Proforma 
 Form IV  Drug compliance form 
 Form V  Patient information sheet 
 Form VI  Consent form 
 Form VII  Withdrawal form  
 Form VIII  Dietary Advice form 
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EXCLUDED FROM TRIAL INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL 
VALUESVALUES 
PHARMACOLOGICAL 
ASSESSMENT 
FURTHER MANAGEMENT 
OF ADVERSE DRUG 
REACTION 
PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
INFORMED CONSENT FORM 
 
WITH 
VARAMAM 
WITHOUT 
VARAMAM 
OUTCOME 
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DATA ANALYSIS: 
 After enrolling the patient for the study, a separate file for each patient will be 
opened and all forms will be kept in the file.  Study No. and Patient No. will be written on 
the top of file for easy identification.  Whenever the patient visits OPD during the study 
period, the respective patient‟s file will be taken and necessary entries will be made at the 
assessment form or other suitable form.  The screening forms will be filed separately.  
The data recordings will be monitored for completion and adverse event by HOD and 
pharmacovigilance committee.  All forms will be further scrutinized in presence of 
Investigators by Sr. Research Officer (Statistics) for logical errors and incompleteness of 
data to avoid any bias.  No modification in the results is permitted for unbiased report. 
 
PHARMACOVIGILANCE:  
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT 
If the trial patient develops any adverse reaction, he/she would be immediately 
withdrawn from the trial and proper management will be given in OPD of National 
Institute of Siddha and the same will be informed to the Pharmaco-vigilance committee of 
NIS. 
References: 
  
1.Text Book Of Orthopedics  (John ebnezer pg.no:674) 
2.www.ncbt.nlm.nih.gov 
3.Varma PulligalinIrupidam (Kanan Rajaram)  
4.Athma Ratchamirtham    (Kandhasami Muthaliyar) 
5.SikitchaRathinaDeepam ( Kannusami Muthaliyar) 
6.SiddhaMaruthuvamPothu  (KuppusamiMuthaliyar) 
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OBSERVATION AND RESULTS 
 
Results of the study were observed with respect to the following 
criteria  
1. Sex Distribution 
2. Age Distribution 
3. Socio Economic Status 
4. Occupational Distribution 
5. Duration of Illness 
6. Diet 
7. Thinai 
8. Paruva Kalam  
9. Gunam 
10. Yaakai Ilakanam 
11. Distribution of Vaatham 
12. Distribution of Pitham 
13. Distribution of Iyyam 
14. Clinical Features 
15. Envagai Thervu 
16. Neikuri 
17. Udal Thaathukkal 
18. Kanmenthiriyam 
19. Outcome Measures 
20.Pain Assessment 
21.Pain Assessment Scale 
22.Result 
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1.SEX DISTRIBUTION: 
 
  
 
Sl. No 
 
Sex 
 
No of Cases 
 
Percentage 
 
1 
 
Males 
 
10 
 
25% 
 
2 
 
Females 
 
30 
 
75% 
 
 
 
 
OBSERVATION: 
 Among 40 patients selected, the disease was found to be in high in females 75% 
and low in males 25% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Male
25%
Female
75%
SEX DISTRIBUTION
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2. AGE DISTRIBUTION: 
 
 
 
 
 
 
 
 
 
OBSERVATION: 
 10% of patients came under the age group between 30-40 years, 30% of patients fell 
under the age group between 41-50 years, 47.5% % of patients were between 51-60 years and 
12.5% of patients were between 61-65years. 
 
 
 
 
 
 
10%
30%
47.5%
13%
1 2 3 4
Sl. No Age No of Cases Percentage 
1 30-40 years 4 10 
2 41-50 years 12 30 
3 51-60 years 19 47.5% 
4 61-65 years 5 12.5% 
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3.SOCIO ECONOMIC STATUS : 
 
 
 
 
Sl. No 
  Socio economic   
No of Cases 
  
Percentage 
 
 
      
 
   
status 
     
 
           
 
            
 
1   Low income 5  12.5%  
 
        
 
2   Moderate income 32  80%  
 
        
 
3   High income 3  7.5%  
 
            
  
 
 
 
socio ecnomic status 
 
 
 
  
OBSERVATION: 
 Among 40 patients , 80%  were Moderate income, 12.50% were Low income, 
7.5% were High income group 
 
 
 
 
  80%  
 
            
80.00%    
 
70.00%    
 
60.00%    
 
50.00%    
 
40.00%    
 
30.00%    
 
10.00% 
0.00% 
12.50%  
7.50% 
 
  
 
 
  
 
    
 
    
 
 
Low 
income 
Moderate 
income 
High 
income 
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Tailor Engineer    Handloom Teacher Coolie Lab 
assistant 
Home 
Maker 
0% 
2.50% 
5% 
2.50% 
5% 10% 
7.50% 
20% 
22.50% 
50% 
 
40% 
 
30% 
55% 60% 
OCCUPATIONAL DISTRIBUTION 
 
 
4.OCCUPATIONAL DISTRIBUTIONS : 
 
 
 
Sl. No Nature of Work No. of Cases Percentage 
1 Home Maker 22 55% 
2 Tailor 3 7.5% 
3 Engineer 2 5% 
4 Handloom weavers 1 2.5% 
5 Teacher 2 5% 
6 Coolie 9 22.5% 
7 Lab assistant 1 2.5% 
 
 
 
 
OBSERVATION: 
 Among 40 cases (55%) were home makers, (7.5%) were tailors, (2.5%) were handloom 
workers and lab assistant and (22.5%) of them were coolie. 
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1-2 YEARS 2-3 YEARS 3-10YEARS 6 MONTHS -1 
YEAR 
UPTO 6 
MONTHS 
10% 
 
5% 
 
0% 
12.50% 
15% 
15% 
20% 
20% 20% 
30% 
 
25% 
32.50% 
35% 
DURATION OF ILLNESS 
5.DURATION OF ILLNESS: 
 
 
 
S.no Duration of illness No of cases Percentage 
1 Upto 6 months 6 15% 
2 6 months – 1 year 13 32.5% 
3 1-2 years 8 20% 
4 2-3 years 8 20% 
5 3-10 years 5 12.5% 
 
 
 
 
 
OBSERVATION: 
 In this study about 12.5%  of cases had 3-10yrs of duration, 20% of cases had 2- 3yrs of 
duration, 20% of cases had 1-2yrs of duration, 32.5% of cases had 6 months-1yr of duration 
and 15% cases had 6 month of Duration of illness. 
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                        DIET HABIT     
    
                                17.5% 
 
 
 
 
82.5% 
 
            vegetarian 
            Non vegetarian 
 
 
 
 
Vegetarian 
Non Vegetarian 
 
 6.DIET : 
 
 
Sl. No 
 
Dietary Habits 
 
No of Cases 
 
Percentage 
 
1 
 
Vegetarian 
 
7 
 
17.5% 
 
2 
 
Non Vegetarian 
 
33 
 
82.5% 
 
 
 
 
 
 
 
OBSERVATION: 
 Among 40 patients, 82.5% of patients were non vegetarian and 17.5% of patients were 
vegetarian. 
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0% 
Paalai Neithal Marutham 
2.5% 
 
Mullai 
20% 
 
10% 
0% 
0% 
Kurinji 
22.5% 
70% 
 
60% 
 
50% 
 
40% 
 
30% 
75% 
100% 
 
90% 
 
80% 
THINAI 
7.THINAI : 
 
Sl. 
No 
Thinai No. of Cases Percentage 
1 Kurinji  0 0% 
2 Mullai  1 2.5% 
3 Marutham  9 22.5% 
4 Neithal  30 75% 
5 Paalai 0 0% 
 
 
 
OBSERVATION: 
 75% of the patients  were from Neithal  and the remaining (22.5%) from  Marutham 
,2.5% from Mullai. 
 
 
 72 
 
 
8. DISRTIBUTION PARUVAKAALAM 
 
 
 
S.NO PARUVA KAALAM NO. OF CASES PERCENTAGE(%) 
1. Kaarkaalam (Aug 18-Oct 17) 0 0 
2. Koothirkaalam (Oct 18-Dec 16) 20 50% 
3. Munpanikaalam (Dec17-Feb 12) 20 50% 
4. Pinpanikaalam (Feb 13-Apr13) 0 0 
5. Elavenilkaalam (Apr 14-Jun 14) 0 0 
6. Muthuvenilkaalam (Jun 15-Aug 17) 0 0 
 
 
 
 
 
 
OBSERVATION: 
 
Among 40 cases, 50% (20) of the cases were affected in Koothirkaalam (Oct 
18-Dec 16) and other 50% (20) of the cases were affected in Munpanikaalam (Dec17 
- Feb 12). 
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
1 2
50% 50%
1
2
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9.GUNAM : 
 
 
Sl. No 
 
Gunam 
 
No of Cases 
 
Percentage 
 
1 
 
Sathuva Gunam 
 
0 
 
0% 
 
2 
 
Raso Gunam 
 
40 
 
100% 
 
3 
 
Thamo Gunam 
 
0 
 
0% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION: 
 
In Gunam 100% of cases had Rasogunam. 
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10.YAAKAI  ILAKKANAM (BODY CONSTITUTION) : 
 
 
 
S.no Yaakaiilak kanam No of cases Percentage 
1 Vaathathegi 10 25% 
2 Pithathegi 5 12.5% 
3 Kabathegi 5 12.5% 
4 Thonthathegi 20 50% 
 
 
 
 
 
OBSERVATION: 
 Out of 50%cases were under Thonthaudal, 25% cases wera Vaatha thegi,12.5% cases 
were Pitha thegi and, 12.5% cases were Kaba thegi . 
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11.A.DISTRIBUTION OF VAATHAM: BEFORE TREATMENT 
  
 
 
 
S.no Vaatham No of cases Percentage 
1 Pranan - - 
2 Abanan - - 
3 Uthanan - - 
4 Viyanan 40 100% 
5 Samanan 40 100% 
6 Nagan - - 
7 Koorman - - 
8 Kirugaran - - 
9 Devathathan - - 
10 Dhananjeyan - - 
 
 
 
 
OBSERVATION: 
 
 In Vaatham, Viyaanan and Samanan were affected in all 40 cases (100%)
0% 0% 0%
100% 100%
0% 0% 0% 0% 0%
VATHAM
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11.B . DISTRIBUTION OF VAATHAM: AFTER TREATMENT 
  
 
 
S.no Vaatham No of cases Percentage 
1 Pranan - - 
2 Abanan - - 
3 Uthanan - - 
4 Viyanan 24 60% 
5 Samanan 26 65% 
6 Nagan - - 
7 Koorman - - 
8 Kirugaran - - 
9 Devathathan - - 
10 Dhananjeyan - - 
 
        
 
OBSERVATION: 
 In Vaatham, Viyaanan were affected in 60% of cases, and Samanan were affected 
in 65% of cases.
60%
65%
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12.A. DISTRIBUTION OF  PITHAM: BEFORE TREATMENT 
 
 
 
S.no Pitham No of cases Percentage 
1 Anarpitham - - 
2 Ranjagapitham - - 
3 Sathagapitham 40 100% 
4 Alosagapitham - - 
5 Prasagapitham - - 
 
 
 
 
 
 
OBSERVATION: 
 
In Pitham, Saathagam was affected in 40 (100%) cases. 
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12.B. DISTRIBUTION OF  PITHAM: AFTER  TREATMENT 
 
 
 
S.no Pitham No of cases Percentage 
1 Anarpitham - - 
2 Ranjagapitham - - 
3 Sathagapitham 26 65% 
4 Alosagapitham - - 
5 Prasagapitham - - 
 
 
 
OBSERVATION: 
 
In Pitham, Saathagam was affected in 26(65%) cases. 
 
 
 
 
 
 
 
 
 
65%
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13. A.DISTRIBUTION OF IYYAM : AFTER TREATMENT 
 
 
 
S.no Iyyam No of cases Percentage 
1 Avalambagam - - 
2 Kilethagam - - 
3 Pothagam - - 
4 Tharpagam - - 
5 Santhigam 40 100% 
 
 
 
 
OBSERVATION: 
 
In Iyam, santhigam was affected in all cases(100%). 
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13.B. DISTRIBUTION OF IYYAM :AFTER TREATMENT 
 
 
 
S.no Iyyam No of cases Percentage 
1 Avalambagam - - 
2 Kilethagam - - 
3 Pothagam - - 
4 Tharpagam - - 
5 Santhigam 16 40% 
 
 
 
 
 
 
 
OBSERVATION: 
 
In Iyam, santhigam was affected in 16 cases (40%). 
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14.A. CLINICAL FEATURES: Before Treatment  
 
Sl. No Clinical Features No of Cases Percentage 
 Swelling         40 100% 
2 Stiffness 29 72.5% 
3 Tenderness 14 35% 
4 Crepitation 37 92.5% 
5 Deformity 7 12.5% 
 
 
 
 
                  
 
 
 
OBSERVATION: 
 In this study, all 100% of cases had Swelling, 72.5% of cases had Stiffness, 35% of cases 
had Tenderness, 92.5% of cases had crepitations, and 12.5% of cases had Deformity. 
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14.B. CLINICAL FEATURES: After Treatment  
 
Sl. No Clinical Features No of Cases Percentage 
1            Swelling         9 22.50% 
2 Stiffness 8 20% 
3 Tenderness 5    12.5% 
4 Crepitation 10 25% 
5 Deformity 7 17.5% 
 
 
 
 
 
 
OBSERVATION: 
 
In this study,  22.5% of cases had Swelling, 20% of cases had Stiffness, 25% of 
cases had crepitations, 17.5%  of cases had Deformity, and 12.5% cases had Tenderness. 
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15A. ENVAGAI THERVUGAL: BEFORE TREATMENT:BEFORE 
TREATMENT 
 
 
 
Sl. 
No 
 
EnvagaiThervugal 
 
No. of Cases 
 
Percentage 
1 Naadi 
 a. Vathapiththam 20 50% 
b. Piththavatham 10 25% 
c. Kabavatham 4 10% 
d. Kabapiththam - - 
2 Sparisam - - 
3 Naa - - 
4 Niram - - 
5 Mozhi - - 
6 Vizhi - - 
7 Malam - - 
8 Moothiram - - 
 
 
OBSERVATION: 
 
The Naadinadai seen in Azhal Keel Vaayu patients were Vathapitham  50%, 
Pithavatham 25 %, Kabavatham . 
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15.B.ENVAGAI THERVUGAL: AFTER TREATMENT:AFTER TREATMENT 
 
 
 
Sl. 
No 
 
EnvagaiThervugal 
 
No. of Cases 
 
Percentage 
1 Naadi 
 a. Vathapiththam 18 45% 
b. Piththavatham 12 30% 
c. Kabavatham 3 7.5% 
d. Kabapiththam -  
2 Sparisam - - 
3 Naa - - 
4 Niram - - 
5 Mozhi - - 
6 Vizhi - - 
7 Malam - - 
8 Moothiram - - 
 
 
OBSERVATION: 
 
 The Naadinadai seen in Azhal Keel Vaayu patients were Vathapitham  45%, 
Pithavatham 30 %, Kabavatham 7.5% . 
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16.A. NEIKKURI: BEFORE TREATMENT 
 
 
 
S.no Neikuri No of cases Percentage 
1 Vaatha neer 
(Aravenaneendathu) 
8 20% 
2 Pithaneer 
(Aazhipolparaviyathu) 
- - 
3 Kaba neer 
(Muthothuninrathu) 
32 80% 
4 Others - - 
 
 
 
OBSERVATION: 
 
Among 40 cases, Vaatha neer was found in 8 cases (20%) and Kaba neer was 
found in 32 cases (80%). 
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16.B.NEIKURI: AFTER TREATMENT 
 
S.No Neikuri No of cases Percentage 
1 Vaatha neer 
(Aravenaneendathu) 
7 17.5% 
2 Pithaneer 
(Aazhipolparaviyathu) 
- - 
3 Kaba neer 
(Muthothuninrathu) 
33 82.5% 
4 Others - - 
 
 
 
 
 
OBSERVATION: 
 
 Among 40 cases, Vaatha neer was  in (17.5%) and Kaba neer was 
found in 82.5%. 
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17.A.UDAL THAATHUKKAL : BEFORE TREATMENT 
 
 
 
S.no Udalthaathukkal No of cases Percentage 
1 Saaram 20 50% 
2 Senneer - - 
3 Oon 40 100% 
4 Kozhuppu 40 100% 
5 Enbu 40 100% 
6 Moolai 20 50% 
7 Sukkilam/Suronitham - - 
 
 
 
 
 
OBSERVATION: 
 
In this study Saaram were affected in50%,  Oon, Kozhuppu and Enbu were 
affected in all 40cases (100%). Moolai was affected in 20 cases (50%). 
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17. B.UDAL THAATHUKKAL :AFTER  TREATMENT 
 
 
 
S.no Udalthaathukkal No of cases Percentage 
1 Saaram 20 10% 
2 Senneer - - 
3 Oon 40 60% 
4 Kozhuppu 40 63% 
5 Enbu 40 65% 
6 Moolai 20 68% 
7 Sukkilam/Suronitham - - 
 
 
      
 
OBSERVATION: 
 
In this study Saaram,  Oon and Enbu were affected in all 40cases (100%). 
Kozhuppu was affected in 20 cases (50%). 
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18.A.KANMENTHIRIYAM : BEFORE TREATMENT 
 
  
S.no Kanmenthiriyam No of cases Percentage 
1 Kai                 -                 - 
2 Kaal 40 100% 
3 Vaai - - 
4 Eruvai - - 
5 Karuvai - - 
 
 
 
 
 
OBSERVATION: 
 
In Kanmenthiriym, Kaal were affected in all 40 cases . 
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18.B.KANMENTHIRIYAM : 
 
  
S.no Kanmenthiriyam No of cases Percentage 
1 Kai                 -                 - 
2 Kaal 28 70% 
3 Vaai - - 
4 Eruvai - - 
5 Karuvai - - 
 
 
 
         
         
 
 
 
OBSERVATION: 
 
In Kanmenthiriym, Kaal were affected in 29 cases . 
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VARMAM  MANIPULATION RESULTS ACCORDING  
TO PAIN SCALE 
OPD CASES CLINICAL IMPROVEMENT (PAIN SCORE) 
 
S.No 
 
OP No 
 
NAME 
AGE/ 
SEX 
PAIN SCORE  
ROMS 
BT AT BT AT 
1. K 95654 RAMA 40/F 8 1 G3 G1 
2.   F 006953 JEYANTHI 36/F 7 1 G3 G1 
3. L 10676 RAVI 55/M 7 1 G3 G1 
4. L 10014 D.MANIMEGALAI 48/F 6 4 G3 G2 
5. K 61602 ELUMALAI 54/M 7 0 G3 G1 
6. H 33143 GUNASUNDARI 44/F 6 1 G2 G1 
7. I 68290 SHANTHI 55/F 6 1 G2 G1 
8. I 20367 MALARKODI 44/F 7 2 G3 G1 
9. J 13408 JAMUNA 56/F 8 3 G3 G2 
10. L16992 LAKSHIMI 38/F 8 1 G3 G1 
11. K 82380 KAMALAKANNAN 54/M 8 2 G3 G1 
12. K 97879 RAMESH 52/M 8 1 G3 G1 
13. J 33561 RANI 64/F 8 1 G3 G1 
14. G  452488 SAVITHRI 62/F 8 6 G3 G1 
15. L17157 SENTHAMARAI 46/F 8 3 G3 G1 
16. J43232 DEIVANAI 51/F 8 1 G3 G1 
17. J84340 RAJENDRAN 57/M 7 2 G3 G1 
18. L00048  MANIMEGALAI 63/F 7 0 G3 G1 
19. L19986 MARIYA 
VICTORIYA 
50/F 6 3 G2 G1 
20. K60567  PRABHU 42/M 7 2 G3 G1 
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PAIN SCORE BEFORE AND AFTER TREATMENT: TRAIL DRUG 
 
 
S.No 
 
OP No 
 
NAM
E 
AGE/ 
SEX 
 
PAIN SCORE 
 
ROMS 
BT AT     BT        AT 
21 I42030 RAJESHWARI 55/F 8 6 G3 G3 
22 K98073        KAVIARASI 50/F 7 3 G3 G1 
23 I58783 BHANUMATHI 60/F 7 1 
 
G3 G1 
24 J44324 CHANDRA 54/F 8 1 G3 G1 
25 J97399 ANNA PUSHPAM 62/F 6 1 G2 G1 
26 L03219 GEETHA 53/F 6 4 G3 G2 
27 J47444 JAWAHAR 57/M 8 1 G3 G1 
28  K60568 RAMYA 39/F 8 1 G3 G1 
29 K5308 JAYA 63/F 4 3 G3 G1 
30 G58335 RAJESH METHA 51/M 7 1 G3 G1 
31 1779-18 REVATHI 48/F 6 2 G3 G1 
32 1774-18 VASANTHA 57/F 8 0 G3 G1 
33 K19651 VIJAYAKUMAR 45/M 6 3 G2 G1 
34 H83252 SUBULAKSHMI 63/F 6 1           G2 G1 
35 K47168 KANCHANA 52/F 7 2           G3 G1 
36 G90503 SELVAM 47/M 8 1           G3 G1 
37 H25390 ANITHA 45/F 8 1 G3 G1 
38 F75898 SUMATHI 56/F 7 2        G3 G1 
39 H09508 SARASU 61/F 8 1 G3 G1 
40 L01690 RANI 45/F 7 1 G2 G11 
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19. OUTCOME MEASURESRESTRICTED MOVEMENT 
ASSESMENT SCALE: 
 
 
 
                        
                                    
 
OBSERVATION: 
 
After the treatment among 40 patients  were observed in (72.5%)  ,(17.5%) Grade 1, 
(35% ), and (7.5% )(,2.5%)of cases were Grade 2. 
 
Series1
0%
20%
40%
60%
80%
100%
0%
17.50%
82.50%
0%
72.50%
17.50%
7.50%
2.50% 0.00% 0.00%
Series1
Series2
GRADING BEFORE 
TREATMENT 
AFTER TREATMENT 
Number 
of 
Patients 
 
Percentage 
% 
GRAD
ING 
Number 
Patients 
 
Percentage % 
 GRADE I 0 0% G3-G1 29 72.5% 
G2-G1 
7           17.5% 
 GRADE II 7 17.5% G3-G2 
 
3 7.5% 
G2-G2 1 
2.5% 
GRADE III 33 82.5%    
GRADE IV 0 0%    
GRADE V 0 0%    
TOTAL 40 100%  40 100% 
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20.A.PAIN ASSESSMENT (VARMAM + TRIAL DRUG) Group A : 
 
 
Pain 
assessment 
(varmam + 
trial drug) 
BEFORE TREATMENT AFTER TREATMENT 
Number of 
Patients 
 
Percentage % 
Number of 
Patients 
 
Percentage % 
No pain (0) 0 0% 2 10% 
Mild ( 1-3 ) 0 0% 16 80% 
Moderate( 4-6 ) 4 20% 2 10% 
Severe( 7-10 ) 16 80% 0 0% 
Total 20 100% 20 100% 
 
 
 
 
 
 
 
 
OBSERVATION: 
 
In this study  (80%) of cases had mild pain,  (10%) of cases had modrate pain and  (10%) 
of cases no pain. 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
No pain (0) Mild ( 1-3 ) Moderate ( 4-6 
)
Severe ( 7-10 )
0% 0%
20%
80%
10%
80%
10%
0%
 95 
 
 
20. B.PAIN ASSESSMENT (TRIAL DRUG ONLY) Group B: 
 
 
Pain assessment 
(trial drug only) 
BEFORE TREATMENT AFTER TREATMENT 
Number of 
Patients 
 
Percentage % 
Number of 
patients 
 
Percentage % 
No pain 0 0 0% 1 5% 
Mild ( 1-3 ) 0 0% 17 85% 
Moderate ( 4-6 ) 6 30% 2 10% 
Severe( 7-10 ) 14 70% 0 0% 
Total 20 100% 20 100% 
 
 
 
 
 
OBSERVATION: 
 
Among the 20 cases, after the treatment the pain was reduced in 20 cases (50%), 
mild pain was present in 17 cases (85%)moderate pain was present in 2case(10%%), and 
no pain was present in 5%. 
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21.PAIN ASSESSMENT: 
 
 
 
 
 
OBSERVATION: 
 
Among 40 patients, in varmam trial drug after the treatment about 85% of the patients 
have mild pain, 10% of patients have moderate pain and 5% of patients had no pain. 
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PAIN 
ASSESSMENT 
 VARMAM + TRIAL DRUG       TRIAL DRUG 
Before 
Treatment 
After Treatment Before Treatment After Treatment 
 No. of 
patients 
% 
No. of 
patients 
% 
No. of 
patients 
% 
No. of 
patients 
% 
No pain 0 0 0% 2 10% 0 0% 1 5% 
Mild ( 1-3 ) 0 0% 16 80% 0 0% 17 85% 
Moderate( 4-6 ) 4 20% 2 10% 6 30% 2 10% 
Severe ( 7-10 ) 16 80% 0 0% 14 70% 0 0% 
Total 20 100% 20 100% 20 100% 20 100% 
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22.PAIN  ASSESMENT SCALE 
 
 
Pain assessment (trial 
drug only) 
BEFORE TREATMENT AFTER TREATMENT 
Number of 
Patients 
 
Percentage % 
Number of 
Patients 
 
Percentage % 
No pain 0 0 0% 3 7.5% 
Mild ( 1-3 ) 0 0% 30 82.5% 
Moderate ( 4-6 ) 10 25% 7 10% 
Severe( 7-10 )         30 75% 0 0% 
Total 40 100% 20 100% 
 
 
 
 
 
OBSERVATION: 
 
Among 40 patients, after the treatment, no pain was found in (7.5%), mild pain 
was found in (82.5%), and moderate pain was found in  (10%). 
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23.RESULTS : 
 
 
RESULT 
NUMBER OF 
CASES 
PERCENTAGE 
Severe  -No pain 3.00 7.5% 
Severe-Mild pain 32 80%% 
Severe-Moderate pain 4 10.0% 
Moderate-No pain 0 0% 
Moderate-Mild pain 1 2.5% 
Total 40 100% 
 
                  
 
 
 
OBSERVATION: 
 
Out of 40 cases, Severe-No pain were obserbed in 7.5%,Severe- Mild pain was 
observed in 80%, Severe-Moderate pain was observed in 10%,Moderate-Mild pain was 
observed in 2.5% 
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INVESTIGATIONS OF BEFORE AND AFTER TREATMENT 
 
S. 
NO. 
OP NO NAME Hb 
gm% 
TRBC 
Million/cumm 
BT AT BT AT 
1 K 95654 RAMA 12.9 13.6 4.1 4.4 
2 F 006953 JEYANTHI 11.4 10.5 4.4 4.0 
3 L 10676 RAVI 16.00 16.5 4.6 4.9 
4 L 10014 D.MANIMEGALAI 12.4 11.7 4.5 4.3 
5 K 61602 ELUMALAI 13.9 13.9 4.6 4.6 
6 H 33143 GUNASUNDARI 13.1 12.8 4.5 4.4 
7 I 68290 SHANTHI 13.5 14.9 4.4 5.3 
8 I 20367 MALARKODI 11.4 10.4 3.9 3.6 
9 J 13408 JAMUNA 12.7 12.6 4.4 4.3 
10 L16992 LAKSHIMI 13.2 13.8 4.4 4.7 
11 K 82380 KAMALAKANNAN 15.4 15.0 4.5 4.5 
12 K 97879 RAMESH 15.5 15.3 5.2 5.2 
13 J 33561 RANI 12.6 13.2 4.4 4.5 
14 G452488 SAVITHRI 11.3 11.7 3.8 3.9 
15 L17157 SENTHAMARAI 8.7 10.2 4.6 4.5 
16 J43232 DEIVANAI 14.9 15.4 4.9 5.1 
17 J84340 RAJENDRAN 11.2 11.4 4.3 4.5 
18 L00048 R.MANIMEGALAI 13.7 13.6 4.8 4.8 
19 L19986 MARIYA 
VICTORIYA 
12.3 12.7 4.0 4.3 
20 K60567 PRABHU 15.00 15.4 4.9 5.1 
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SL.NO 
 
 
OP NO 
 
 
NAME 
Hb gm% TRBC Million/cumm 
Before 
Treatme
nt 
After 
treatment 
Before 
treatment 
After 
Treatment 
21 I42030 RAJESHWARI 12.1 12.9 4.6 4.2 
22 K98073  KAVIARASI 11.9 12.3 5.1 5.5 
23 I58783 BHANUMATHI 11.4 14.1 4.5 4.4 
24 J44324 CHANDRA 13.1 13.4 5.3 4.5 
25 J97399 ANNA 
PUSHPAM 
12.7 12.6 4.4 4.3 
26 L03219 GEETHA 12.3 11.9 5.3 5 
27 J47444 JAWAHAR 15.5 15.3 4.9 4.8 
28  K60568 RAMYA 13.7 11.6 5.1 5.2 
29 K5308 JAYA 13.5 14.9 5 5 
30 G58335 RAJESH 
METHA 
16.1 16.3 5.4 5.2 
31 1779-18 REVATHI 11.9 14.4 4.2 5.3 
32 1774-18 VASANTHA 10.2 13.3 4.8 4.6 
33 K19651 VIJAYAKUMA
R 
12.1 12.7 5.1 5.2 
34 H83252 SUBULAKSHM
I 
13.4 13.5 5 5.1 
35 K47168 KANCHANA 12.1 13.2 4.3 4.5 
36 G90503 SELVAM 11.5 10.9 5 4.7 
37 H25390 ANITHA 14.7 13.9 4.5 4.4 
38 F75898 SUMATHI 14.8 14.4 5.4 5 
39 H09508 SARASU 11.3 12 4.5 4.6 
40 L01690 RANI 14.5 14.8 4.9 5.1 
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INVESTIGATIONS OF BEFORE AND AFTER TREATMENT 
 
  
S.NO 
  
IP NO T.CHOLESTE
ROL 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
TGL 
(mg/dl) 
BT AT BT AT BT AT BT AT BT AT 
1 K 95654 189 216 36 41 105 127 78 75.1 248 243 
2 F 006953 209        179 65 59.4 102 93.9 19 13.5 98 67.5 
3 L10676 148 147 56 55 70 68.1 13.7 14 68.5 70 
4 L 10014 262 258 56 48 143 151 43 74 214 220 
5 K 6160 212 230 51 57.7 111 125 12 18.5 63 92.5 
6 H 33143 132 147 48 50.6 67 68.1 18 13.1 88 65.4 
7 I 68290 261 228 68 86 140 123 12 56 61 64 
8 I 20367 201 171 53 42 113 96 31 32 158 159 
9 J 13408 212 199 55 53.9 110 128 23 27 107 95 
10 L16992 209 228 55 58 106 112 32 36 115 139 
11 K82380 186 198 39 37 98 105 42 51 212 254 
12 K97879 227 222 49 53 113 121 21 33 107 165 
13 J33561 224 215 54 58 116 139 22 36 112 153 
14 G45248 173 172 61 70 79 81 12 30 62 80 
15 L17157 195 190 42 52 99 90 25 26 125 130 
16 J43232 210 195 50 49 105 111 30 39 149 196 
17 J84340 194 213 59 59 115 169 23 18.3 101 91.4 
18 L00048 218 235 56 53 121 120 27 21 134 107 
19 L19986 225 184 60 55 116 113 26 21 128 104 
20 K60567 135 147 34 45 70 82 17 37 143 183 
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S.NO OP NO T.CHOLESTERO
L 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
TGL 
(mg/dl) 
BT AT BT AT BT AT BT AT BT A
T 
21   I 42030 191 196 53 53 96 99 24 27 118 12
6 
22 K98073 160 165 50 50 77 75 18 20 90 96 
23 I58783 193 206 47 52 99 114 28 21 140 10
3 
24 J44324 236 258 58 67 120 146 16 20 80 10
4 
25 J97399 210 237 48 57 117 141 36 31 180 16
5 
26 L03219 172 189 56 66 82 90 21 11 105 58 
27 J47444 222 257 54 60 111 132 31 32 156 15
9 
28 K60568 212 119 53 48 108 58 19 20 97 45 
29 K5308 196 219 56 60 92 123 19 19 93 95 
30 G58335 233 244 47 46 138 133 34 36 173 18
2 
31 1779-18 173 163 46 47 98 101 20 23 99 11
3 
32 1774-18 214 242 58 57 122 118 27 25 135 12
9 
33 K19651 201 210 56 58 108 121 29 35 147 16
7 
34 H83252 228 228 52 48 137 123 21 24 105 12
3 
35 K47168 305 300 77 70 176 170 21 25 103 10
5 
36 G90503 202 178 64 52 110 105 14 31 72 15
7 
37 H25390 224 193 62 45 122 109 64 58 320 29
0 
38 F75898 150 158 50 43 110 89 20 23 102 11
3 
39 H09508 212 201 53 47 108 111 19 20 97 10
0 
40 L06690 213 228 51 57 109 119 15 20 77 10
2 
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INVESTIGATIONS  OF BEFORE AND AFTER 
TREATMENT 
 
S. N OP.NO TC 
Cells/µL 
DC ESR 
P L Mxd ½ HR 1 HR 
BT AT BT A T B T A
T 
BT A T BT AT BT AT 
1 K 95654 7.600 9000 65 69 30 27 05 02 16 32 24 50 
2   F 006953 6.000 7000 57 67 39 30 04 03 34 40 24 50 
3 L 10676 6.200 5,900 75 75 20 21 05 04 16 32 02 04 
4 L 10014 7.600 8200 65 67 33 29 02 02 10 8 22 18 
5 K 61602 7.500 7100 79 62 18 35 03 03 10 08 20 16 
6 H 33143 6.800 6200 60 65 30 30 10 05 8 12 16 24 
7 I 68290 6.100 6300 55 65 42 42 03 02 06 12 18 18 
8 I 20367 3.600 3.700 60 65 32 29 08 06 20 30 40 35 
9 J 13408 6.900 7.200 55 58 41 38 04 02 30 06 60 12 
10 L16992 7.400 7.400 55 53 43 41 03 06 8 20 18 30 
11 K 82380 8.200 7.000 65 69 31 27 04 04 4 08 10 18 
12 K 97879 6.500 4.700 75 60 22 37 03 03 04 04 08 08 
13 J 33561 4.900 5.000 65 65 31 32 04 03 06 08 14 20 
14   G45248 4.800 4.900 62 63 34 33 04 03 34 35 50 52 
15 L17157 9.000 9.100 75 75 20 21 02 04 14 18 20 30 
16 J43232 8.600 9.700 69 73 28 24 03 03 16 24 34 50 
17 J84340 6.600 6.600 65 64 30 32 05 03 8 10 0 20 
18 L00048 9.500 8.500 68 69 26 27 05 05 20 60 40 30 
19 L19986 6.400 6.200 59 58 39 39 02 03 16 40 32 50 
20 K60567 6.600 6.500 66 65 30 30 02 03 06 12 14 20 
 104 
 
INVESTIGATIONS OF BEFORE AND AFTER TREATMENT 
  
S. N O OP. NO TC 
(million 
cu.mm) 
DC ESR 
N L Mxd ½ HR 1 HR 
BT AT B T A 
T 
B 
T 
A
T 
B 
T 
A 
T 
B 
T 
A 
T 
B 
T 
A 
T 
21     I 42030 7.000 7.400 77 53 21 42 05 05 16 10 32 22 
22 K98073 7.300 7.200 69 60 26 32 04 04 12 15 42 30 
23 I58783 7.300 7.400 65 60 30 41 05 05 14 16 32 16 
24 J44324 6.000 6.000 60 57 36 40 04 05 6 10 12 22 
25 J97399 4.900 4.9 38 47 50 44 02 04 10 8 20 16 
26 L03219 5.400 4.700 61 62 36 36 03 02 16 14 32 40 
27    J47444 8.700 8.400 60 73 31 36 23 02 14 14 24 30 
28 K60568 6.500 6.500 61 62 35 34 04 04 8 14 20 24 
29 K5308 9.200 9.600 70 70 27 41 03 02 4 8 10 12 
30    G58335 6.800 6.200 65 58 31 39 04 03 14 12 34 40 
31 1779-18 5.2 5.3 66 60 26 34 03 03 4 6 20 12 
32 1774-18 4.600 4.600 61 55 32 33 02 02 10 24 26 50 
33 K19651 5.000 4.700 55 52 40 42 02 01 20 20 40 42 
34 H83252 5.000 5.100 73 60 23 33 01 01 14 18 28 26 
35 K47168 4.300 4.500 56 56 40 40 04 04 22 20 46 44 
36 G90503 5.000 4.700 52 55 42 38 02 03 20 10 46 22 
37 H25390 4.500 4.400 57 45 39 51 01 01 14 6 30 12 
38 F75898 5.4 5.0 62 62 30 30 8 8 10 2 22 4 
39 H09508 4.600 4.800 70 73 24 25 06 02 10 14 20 28 
40 L06690 6.600 4.600 65 65 30 32 05 03 8 16 18 14 
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INVESTIGATIONS OF BEFORE AND AFTER TREATMENT 
 
Sl. 
No 
IP NO Serum bilirubin (mg/dl) GLUCOSE 
PROFILE 
Direct Indirect Tota
l 
FAST P.P. 
BT AT BT AT BT AT BT AT BT AT 
1 K 95654 0.3 0.36 0.6 0.6 0.9 1.0 90 95 108 175 
2   F 006953 0.3 0.23 0.4 0.3 0.4 0.3 83 95 90 86 
3 L 10676 0.4 0.6 0.5 0.8 0.9 1.4 90 83 108 76 
4 L 10014 0.2 0.3 0.3 0.3 0.5 0.6 127 110 160 148 
5 K 61602 0.2 0.4 0.3 0.2 0.5 0.6 89 95 103 110 
6 H 33143 0.1 0.3 0.2 0.5 0.3 0.8 117 114 110 127 
7 I 68290 0.2 0.4 0.4 0.4 0.6 0.8 360 299 455 435 
8 I 20367 0.4 0.4 0.8 0.6 1.2 1.0 117 112 124 117 
9 J 13408 0.2 0.2 0.3 0.2 0.5 0.4 217 214 412 397 
10 L16992 0.1 0.1 0.3 0.7 0.4 0.8 92 104 145 162 
11 K 82380 0.5 0.4 1.0 0.6 1.5 1.0 127 126 143 136 
12 K 97879 0.4 0.3 0.7 0.6 1.1 0.9 113 104 166 158 
13 J 33561 0.1 0.1 0.3 0.3 0.4 0.4 118 181 229 287 
14   G452488 0.1 0.1 0.1 0.1 0.2 0.2 86 85 105 121 
15 L17157 0.2 0.9 0.6 0.6 0.8 0.8 107 110 109 105 
16 J43232 0.2 0.2 0.4 0.3 0.6 0.5 130 100 188 104 
17 J84340 0.1 0.2 0.1 0.2 0.2 0.4 104 110 108 122 
18 L00048 0.3 0.4 0.7 0.8 1.0 1.2 101 104 112 116 
19 L19986 0.3 0.3 0.6 0.8 1.2 1.2 105 106 113 115 
20 K60567 0.6 0.5 0.6 0.5 1.2 1.0 91 94 106 97 
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Sl. 
No 
IP NO 
Serum bilirubin (mg/dl) 
GLUCOSE 
PROFILE 
Direct Indirect Total FAST P.P. 
BT AT BT AT BT AT BT AT BT AT 
21     I 42030 0.1 0.3 0.7 0.7 1.0 1.0 128 120 212 200 
22 K98073 0.5 0.4 0.3 0.2 0.5 0.6 97 100 152 140 
23 I58783 0.4 0.2 0.2 0.3 0.7 0.5 76 88 172 168 
24 J44324 0.1 0.3 0.2 0.4 0.4 0.7 97 110 106 120 
25 J97399 0.1 0.4 0.4 1.0 0.2 1.4 93 99 147 159 
26 L03219 0.2 0.6 0.3 0.3 0.5 0.8 106 110 112 116 
27    J47444 0.2 0.2 0.3 0.5 0.5 0.7 106 110 202 190 
28 K60568 0.1 0.1 0.3 0.3 0.4 0.4 137 128 244 228 
29 K5308 0.3 0.1 0.2 0.2 0.3 0.3 114 102 139 111 
30   G58335 0.3 0.3 1.0 0.7 1.4 1.0 94 108 110 123 
31 1779-18 0.6 0.2 0.4 0.4 0.6 0.6 100 97 157 146 
32 1774-18 0.3 0.3 0.5 0.6 0.8 0.9 102 86 132 102 
33 K19651 0.3 0.5 0.4 0.4 0.9 0.9 115 110 160 138 
34 H83252 0.4 0.3 0.2 0.3 0.5 0.6 115 126 189 190 
35 K47168 0.2 0.8 0.7 0.4 1.1 1.2 114 110 109 100 
36 G90503 0.2 0.1 0.2 0.3 0.4 0.4 110 109 120 157 
37 H25390 0.1 0.3 0.5 0.8 0.7 1.1 114 160 105 195 
38 F75898 0.2 0.3 0.3 0.3 0.5 0.6 141 88 217 124 
39 H09508 0.4 0.4 0.3 0.3 0.5 0.5 258 238 383 378 
40 L06690 0.2 0.3 0.5 0.2 0.8 0.5 89 111 110 182 
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INVESTIGATIONS  OF BEFORE AND AFTER TREATMENT 
 
S. N OP.NO TC 
Cells/µL 
DC ESR 
P L Mxd ½ HR 1 HR 
BT AT BT A T B T AT B 
T 
A T BT AT BT AT 
1 K 95654 7.600 9000 65 69 30 27 05 02 16 32 24 50 
2   F 006953 6.000 7000 57 67 39 30 04 03 34 40 24 50 
3 L 10676 6.200 5,900 75 75 20 21 05 04 16 32 02 04 
4 L 10014 7.600 8200 65 67 33 29 02 02 10 8 22 18 
5 K 61602 7.500 7100 79 62 18 35 03 03 10 08 20 16 
6 H 33143 6.800 6200 60 65 30 30 10 05 8 12 16 24 
7 I 68290 6.100 6300 55 65 42 42 03 02 06 12 18 18 
8 I 20367 3.600 3.700 60 65 32 29 08 06 20 30 40 35 
9 J 13408 6.900 7.200 55 58 41 38 04 02 30 06 60 12 
10 L16992 7.400 7.400 55 53 43 41 03 06 8 20 18 30 
11 K 82380 8.200 7.000 65 69 31 27 04 04 4 08 10 18 
12 K 97879 6.500 4.700 75 60 22 37 03 03 04 04 08 08 
13 J 33561 4.900 5.000 65 65 31 32 04 03 06 08 14 20 
14   G45248 4.800 4.900 62 63 34 33 04 03 34 35 50 52 
15 L17157 9.000 9.100 75 75 20 21 02 04 14 18 20 30 
16 J43232 8.600 9.700 69 73 28 24 03 03 16 24 34 50 
17 J84340 6.600 6.600 65 64 30 32 05 03 8 10 0 20 
18 L00048 9.500 8.500 68 69 26 27 05 05 20 60 40 30 
19 L19986 6.400 6.200 59 58 39 39 02 03 16 40 32 50 
20 K60567 6.600 6.500 66 65 30 30 02 03 06 12 14 20 
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INVESTIGATIONS OF BEFORE AND AFTER TREATMENT 
  
S. N O OP. NO 
TC 
(million/ cu.mm) 
DC ESR 
N L Mxd ½ HR 1 HR 
BT AT 
B
 
T 
A
 
T 
B
 
T 
AT 
B 
T 
A
T 
B
  
A
T 
B 
T 
A 
T 
21     I 42030 7.000 7.400 77 53 21 42 05 05   16 10 32 22 
22 K98073 7.300 7.200 69 60 26 32 04 04 12 15 42 30 
23 I58783 7.300 7.400 65 60 30 41 05 05 14 16 32 16 
24 J44324 6.000 6.000 60 57 36 40 04 05 6 10 12 22 
25 J97399 4.900 4.9 38 47 50 44 02 04 10 8 20 16 
26 L03219 5.400 4.700 61 62 36 36 03 02 16 14 32 40 
27    J47444 8.700 8.400 60 73 31 36 23 02 14 14 24 30 
28 K60568 6.500 6.500 61 62 35 34 04 04 8 14 20 24 
29 K5308 9.200 9.600 70 70 27 41 03 02 4 8 10 12 
30    G58335 6.800 6.200 65 58 31 39 04 03 14 12 34 40 
31 1779-18 5.2 5.3 66 60 26 34 03 03 4 6 20 12 
32 1774-18 4.600 4.600 61 55 32 33 02 02 10 24 26 50 
33 K19651 5.000 4.700 55 52 40 42 02 01 20 20 40 42 
34 H83252 5.000 5.100 73 60 23 33 01 01 14 18 28 26 
35 K47168 4.300 4.500 56 56 40 40 04 04 22 20 46 44 
36 G90503 5.000 4.700 52 55 42 38 02 03 20 10 46 22 
37 H25390 4.500 4.400 57 45 39 51 01 01 14 6 30 12 
38 F75898 5.4 5.0 62 62 30 30 8 8 10 2 22 4 
39 H09508 4.600 4.800 70 73 24 25 06 02 10 14 20 28 
40 L06690 6.600 4.600 65 65 30 32 05 03 8 16 18 14 
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INVESTIGATIONS OF BEFORE AND AFTER 
TREATMENT 
 
Sl. 
No 
OP NO 
SGOT 
(IU/dl) 
SGPT 
(IU/dl) 
Al.pho 
(U/dl) 
Albumi
n 
(g/dl) 
Globuli
n 
(g/dl) 
T.Protein 
(g/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT 
1  K 95654 21 22 28 40.9 100 107 3.9 3.9
6 
3.0 3.9 7.5 7.87 
2  F 006953 12 12.1 12 10.5 66 56 3.7 3.6 3.5 3.4 7.3 6.97 
3   L 10676 26 18.6 27 22 73 73 3.8 3.5 3.4 3.3 7.2 6.87 
4  L 10014 17 17 09 20 56 58 4.1 3.6 2.9 2.7 7.0 7.2 
5  K 61602 34 25.1 47 19.3 61 55 3.9 3.9 3.0 3.2 7.0 7.2 
6  H 33143 19 17.3 12 16.7 71 67 3.8 3.8 3.4 3.8 7.2 7.9 
7  I 68290 18 23 14 25 77 78 4.2 3.3 3 3.1 7.2 7.4 
8  I 20367 22 24 19 20 65 56 3.5 3.5 4.2 4.9 8.3 8.00 
9  J 13408 22 16 24 18 87 84 4.0 3.8 2.7 2.9 6.7 6.7 
10  L16992 16 16 09 11 72 72 3.8 3.7 3.5 3.6 7.3 7.2 
11  K 82380 14 15 18 14 86 84 4.3 4.0 3.3 3.3 7.6 7.3 
12  K 97879 16 17 08 15 79 79 4.2 4.1 2.3 2.9 6.5 6.9 
13  J 33561 20 22 16 19 100 104 3.8 3.2 3.3 3.1 7.1 7.2 
14  G45248 16 18 15 15 108 107 3.2 3.1 2.2 2.1 7.4 7.1 
15   L17157 18 20 16 18 96 95 3.7 3.9 3.5 3.6 7.2 7.00 
16  J43232 18 20 20 20 66 62 3.6 3.6 3.3 3.1 6.8 6.7 
17  J84340 19 19.5 20.2 20 99 98 3.6 3.3 3.1 3.8 6.7 6.9 
18  L00048 16 16 19 14 107 118 3.7 3.5 3.8 3.9 7.5 7.5 
19  L19986 21 20 23 22 148 100 3.6 3.2 3.3 3.1 6.9 7.2 
20  K60567 19 15 23 26 76 67 3.2 3.1 2.2 2.5 7.1 7.2 
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INVESTIGATIONS OF  BEFORE AND AFTER 
TREATMENT 
 
Sl. 
No 
OP NO 
SGOT 
(IU/dl) 
SGPT 
(IU/dl) 
Al.pho 
(U/dl) 
Albumin 
(g/dl) 
Globulin 
(g/dl) 
T. 
Protein 
(g/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT 
21 I 42030 10 19 19 18 71 80 3.8 5.0 3.2 3.0 7.7 8.0 
22 K98073 18 22 24 25 57 67 3.7 3.9 3.1 3.2 6.8 7.0 
23 I58783 15 15 16 10 66 70 3.8 3.7 2.8 3.0 6.6 6.7 
24 J44324 18 20 24 23 65 66 3.9 3.7 2.3 2.2 6.7 6.9 
25 J97399 21 19 21 17 79 85 4.2 3.8 3.1 3.1 7.2 6.9 
26 L03219 12 19 13 19 97 91 4.0 3.8 2.7 2.9 6.7 6.8 
27 J47444 19 18 23 17 73 62 3.4 3.7 3.3 3.5 7.0 7.2 
28 K60568 16 19 09 19 64 77 04 4.2 3 2.8 7 7.1 
29 K5308 22 21 20 24 88 72 4.5 4.3 3.3 3.3 7.8 7.6 
30 G58335 32 25 18 20 97 93 4.4 4.4 3.1 3.0 7.5 7.4 
31 1779-18 10 12 10 20 104 110 4.2 4.1 3.1 3.2 7.3 7.2 
32 1774-18 23 24 28 22 86 99 4.6 4.4 3.0 2.7 7.6 7.1 
33 K19651 21 19 21 17 79 85 4.2 3.8 3.1 3.1 7.2 6.9 
34 H83252 12 19 13 19 97 91 4.0 3.8 2.7 2.9 6.7 6.8 
35 K47168 19 18 23 17 73 62 3.4 3.7 3.3 3.5 7.0 7.2 
36 G90503 16 19 09 19 64 77 04 4.2 3 2.8 7 7.1 
37 H25390 22 21 20 24 88 72 4.5 4.3 3.3 3.3 7.8 7.6 
38 F75898 32 25 18 20 97 93 4.4 4.4 3.1 3.0 7.5 7.4 
39 H09508 10 12 10 20 104 110 4.2 4.1 3.1 3.2 7.3 7.2 
40 L06690 23 24 28 22 86 99 4.6 4.4 3.0 2.7 7.6 7.1 
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INVESTIGATIONS OF  BEFORE AND AFTER 
TREATMENT 
  
Sl. 
No 
OP NO 
Calcium 
(mg/dl) 
Uric 
acid 
mg/dl 
TGL 
mg/dl 
Urea 
(g/dl) 
Creatinine 
(g/dl) 
BT AT BT AT BT AT BT AT BT AT 
1  K 95654 8.9 8.8 5.8 5.1 280 270 13 14.1 0.9 0.8 
2  F 006953 8.9 9.8 4.2 3.6 98 67 22 26 0.8 0.8 
3   L 10676 9.1 8 7.5 6.0 57 68.5 20 14 1.0 0.98 
4  L 10014 8.4 8.9 5.4 5.3 214 250 18 12 0.9 0.8 
5  K 61602 8.3 9.6 5.2 5.2 63 92 16 8.9 0.9 0.82 
6  H 33143 9.3 7.9 3.2 2.5 88 65 23 30 0.9 0.86 
7  I 68290 9.6 9.9 2.6 2.2 61 78 15 18 0.8 0.7 
8  I 20367 7.1 7.3 2.1 2.2 158 159 18 14 0.8 0.9 
9  J 13408 8.3 9.3 5.4 4.9 107 95 17 21 0.7 0.7 
10  L16992 8.8 8.7 4.2 4.7 115 139 21 19 0.8 0.7 
11  K 82380 9.8 9.2 5.9 5.8 212 259 13 18 1.0 1.0 
12  K 97879 10.2 8.1 6.1 5.4 107 165 20 17 1.1 1.1 
13  J 33561 7.9 8.7 3.0 4.1 112 119 17 20 0.8 0.9 
14  G45248 8.4 8.2 4.1 3.4 64 75 19 16 0.7 0.9 
15   L17157 9.1 9.8 3.8 3.2 125 130 15 20 0.8 0.7 
16  J43232 8.9 9.3 5.1 4.9 149 196 18 16 0.9 1.0 
17  J84340 8.7 8.9 5.1 5.4 91 109 29 28 0.9 1.0 
18  L00048 8.9 9.7 6.9 4.7 134 107 29 23 1.0 1.0 
19  L19986 9.5 9.8 3.2 3.0 215 230 19 18 0.8 1.0 
20  K60567 8.1 8.0 2.3 2.5 134 138 20 19 0.9 1.1 
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Sl. 
No 
OP NO 
Calcium 
(mg/dl) 
Uric 
acid 
mg/dl 
TGL 
mg/dl 
Urea 
(g/dl) 
Creatinine 
(g/dl) 
BT AT BT AT BT AT BT AT BT AT 
21     I 42030 9.7 9.9 5.2 5.3 118 180 21 25 0.8 0.9 
22 K98073 8.8 9.1 5.1 5.2 90 99 23 25 0.8 1.0 
23 I58783 9.9 8.5 3.5 3.9 103 140 21 24 0.8 0.9 
24 J44324 9.2 9.7 4.6 4.2 80 87 24 21 0.8 1.1 
25 J97399 8.1 9.6 3.1 4.6 180 165 15 14 0.9 0.9 
26 L03219 8.9 9.7 6.9 4.7 134 107 29 23 1.0 1.0 
27    J47444 8.9 7.6 5.8 5.9 156 159 14 13 1.1 1.0 
28 K60568 8.3 9.6 5.2 5.2 63 92 16 8.9 0.9 0.82 
29 K5308 9.3 7.9 3.2 2.5 88 65 23 30 0.9 0.86 
30   G58335 9.6 9.9 2.6 2.2 61 78 15 18 0.8 0.7 
31 1779-18 7.1 7.3 2.1 2.2 158 159 18 14 0.8 0.9 
32 1774-18 8.3 9.3 5.4 4.9 107 95 17 21 0.7 0.7 
33 K19651 8.8 8.7 4.2 4.7 115 139 21 19 0.8 0.7 
34 H83252 9.8 9.2 5.9 5.8 212 259 13 18 1.0 1.0 
35 K47168 10.2 8.1 6.1 5.4 107 165 20 17 1.1 1.1 
36 G90503 7.9 8.7 3.0 4.1 112 119 17 20 0.8 0.9 
37 H25390 8.4 8.2 4.1 3.4 64 75 19 16 0.7 0.9 
38 F75898 9.1 9.8 3.8 3.2 125 130 15 20 0.8 0.7 
39 H09508 8.9 9.3 5.1 4.9 149 196 18 16 0.9 1.0 
40 L06690 8.7 8.9 5.1 5.4 91 109 29 28 0.9 1.0 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
  
 
 
 
S. NO 
 
 
 
OP NO 
URINE 
Before Treatment After Treatment 
Albu 
min 
Sugar Deposits Alb 
umi 
n 
Sugar Deposits 
F PP 
Pus 
Cells 
Epi
Cels 
F PP 
Pus 
Cells 
Epi. 
Cells 
1  K 95654 NIL NIL NIL 1-3 1-2 NIL NIL NIL 1-2 1-2 
2  F 006953 NIL NIL NIL 4-2 2-4 NIL NIL NIL 4-2 2-4 
3   L 10676 NIL NIL NIL 1-3 2-4 NIL NIL NIL 1-3 2-4 
4  L 10014 NIL NIL NIL 6-8 5-7 NIL NIL NIL 7-8 6-7 
5  K 61602 NIL NIL NIL 1-3 2-4 NIL NIL NIL 1-3 2-4 
6  H 33143 NIL NIL NIL 1-3 1-2 NIL NIL NIL 1-3 1-2 
7  I 68290 NIL ++ +++ 5-6 2-4 NIL ++ +++ 5-6 2-4 
8  I 20367 NIL NIL NIL 2-4 2-4 NIL NIL NIL 1-2 2-3 
9  J 13408 NIL + ++ 1-2 2-4 NIL ++ +++ 2-4 6-8 
10  L16992 NIL NIL NIL 2-4 3-5 NIL NIL NIL 2-3 3-4 
11  K 82380 NIL NIL NIL 6-8 2-4 NIL NIL NIL 6-8 7-8 
12  K 97879 NIL NIL NIL 2-3 2-3 NIL NIL NIL 2-3 2-3 
13  J 33561 NIL NIL + 2-3 1-2 NIL NIL + 2-4 1-2 
14  G45248 NIL NIL NIL 2-3 2-3 NIL NIL NIL 6-8 4-6 
15   L17157 NIL NIL NIL 4-5 2-3 NIL NIL NIL 4-5 2-3 
16  J43232 NIL NIL NIL 2-4 3-5 NIL NIL NIL 2-3 2-4 
17  J84340 NIL NIL NIL 2-3 2-4 NIL NIL NIL 2-3 3-5 
18  L00048 NIL NIL NIL 6-7 6-4 NIL NIL NIL 6-7 6-4 
19  L19986 NIL NIL NIL 6-7 2-4 NIL NIL NIL 5-6 3-5 
20  K60567 NIL NIL NIL 1-2 1-2 NIL NI NIL 4-5 4-6 
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S. 
NO 
 
 
 
OP NO 
URINE 
Before Treatment After Treatment 
Albu 
min 
Sugar Deposits Albu min Sugar Deposits 
F PP Pus 
Cells 
Epi. 
cells 
F PP Pus 
Cells 
Epi. 
Cells 
21     I 42030 NIL NIL NIL 1-2 2-4 NIL NIL NIL 1-2 2-4 
22 K98073 NIL NIL NIL 1-2 2-3 NIL NIL NIL 1-2 2-3 
23 I58783 NIL NIL NIL 2-3 2-3 NIL NIL NIL 1-3 3-5 
24 J44324 NIL NIL NIL 4-5 2-3 NIL NIL NIL 4-5 2-3 
25 J97399 NIL NIL NIL 3-5 3-5 NIL NIL NIL 1-3 1-3 
26 L03219 NIL NIL NIL 1-3 1-3 NIL NIL NIL 1-3 1-3 
27    J47444 NIL NIL NIL 1-2 6-8 NIL NIL NIL 10-12 6-8 
28 K60568 NIL NIL NIL 1-2 2-4 NIL NIL NIL 1-2 1-4 
29 K5308 NIL NIL NIL 2-4 1-2 NIL NIL NIL 4-6 3-5 
30   G58335 NIL NIL NIL 2-3 2-3 NIL NIL NIL 2-4 2-4 
31 1779-18 NIL NIL NIL 2-4 2-4 NIL NIL NIL 2-4 2-4 
32 1774-18 NIL NIL NIL 3-5 1-3 NIL NIL NIL 2-4 2-4 
33 K19651 NIL NIL NIL 2-3 1-2 NIL NIL NIL 2-3 1-2 
34 H83252 NIL NIL NIL 4-6 2-4 NIL NIL NIL 4-6 2-4 
35 K47168 NIL NIL NIL 2-4 1-3 NIL NIL NIL 2-4 1-3 
36 G90503 NIL NIL NIL 4-6 3-5 NIL NIL NIL 4-6 3-5 
37 H25390 NIL NIL NIL 1-3 3-5 NIL NIL NIL 2-4 2-4 
38 F75898 NIL NIL NIL 2-3 2-3 NIL NIL NIL 2-4 2-4 
39 H09508 NIL NIL NIL 1-2 1-3 NIL NIL NIL 1-2 1-3 
40 L06690 NIL NIL NIL 2-3 2-3 NIL NIL NIL 1-3 2-4 
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STATISTICAL ANALYSIS: 
  
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross-tabulations were 
performed. The quantity variables were expressed as Mean ± Standard Deviation and 
qualitative data as percentage. A probability value of <0.05 was considered to indicate as 
statistical significance. Paired ‗t‘ test was performed for determining the significance 
between before and after treatment. 
  PAIN ASSESSMENT SCALE BEFORE AND AFTER TREATMENT: 
 
 
Pain scale 
 
Sample size 
 
Mean 
Standard 
deviation 
95% 
confidence 
interval 
 
Significant 
Before 
treatment 
40 7.125       0.9388 6.82-7.42 
 
 
 
p<0.0001. After 
treatment 
40 1.9 1.317 1.49 - 2.31 
 
 
PAIN ASSESSMENT AT START OF TREATMENT BETWEEN TWO GROUPS: 
 
 Sample 
size 
Mean Standard 
deviation 
 
‘t’ value 
 
‘p’ value 
Without 
Varmam 20 7 1.076 
0.0017 0.99 
With 
Varmam 
20 7.25 0.7864 
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PAIN ASSESSMENT AT END OF TREATMENT BETWEEN TWO GROUPS 
 
 
 
  
Sample 
size 
 
Mean 
 
Standard 
deviation 
 
‘t’ value 
 
‘p’ value 
Without 
Varmam 
20 1.85 1.348  
0.0027 
 
0.0998 
With 
Varmam 
20 1.95 1.317 
 
 
There is no significant difference between with and without varmam treatment 
groups before the start of treatment. 
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DISCUSSION 
 
The purpose of this trail is evaluate to the therapeutic efficacy of the drug 
“Kandathri Chooranam” (Internal), “Erandai Thylam” (External) to reduce pain, 
swelling, restriction of movements and other clinical symptoms of Azhal Keel Vayu. 
 
The clinical features of Azhal Keel Vayu can be correlated with Osteoarthritis in 
modern science. OA is a degenerative joint disease involving the cartilage and many of its 
surrounding tissues. In addition to damage and loss of articular cartilage, there is 
remodelling of subarticular bone, osteophyte formation, ligamentous laxity, weakening of 
periarticular muscles and in some cases, synovial inflammation. 
 
The drugs which possess Anti-Vatha property as mentioned in Siddha literature 
were selected and the trial drugs were prepared in Gunapadam practical laboratory of 
National Institute of Siddha, after getting proper authentication of raw drugs from the 
Medicinal botany department at NIS, Chennai 47, under the supervision of the members 
of the teaching faculty and guided by the Head of the Department of Sirappu 
Maruthuvam of the National Institute of Siddha, Chennai - 47. The trial drug was 
prepared by the standard operating procedure as mentioned in the protocol. 
 
The Biochemical qualitative analysis was done at the Biochemistry lab of NIS. 
The Bio-chemical analysis of “Kandathri chooranam” had shown the presence of 
Chloride, Carbonate, Calcium, Magnesium, Ammonium, Mercury, Arsenic, Starch, 
Reducing Sugar  Lead, Aluminium, ,Iron, Zinc Tannic acid, starch, unsaturated 
compound and Alkaloids. 
 
The clinical study was conducted with a well defined protocol and a proper 
proforma after the approval of the Institutional Ethical Committee. After screening 
patients reporting at the OPD of department of Sirappu Maruthuvam, 40 cases were 
selected for induction to the trial. Before enrollment into the trial the informed consent 
was obtained from the patients. 
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 40 patients of both genders were recruited for this study. Among the 40 patients 
were treated in the OPD/IPD . Out of 40patients, were 20 patients had treated under the 
varmam therapy along with the trial drugs. Rest of them 20 patients were treated  trial 
drug  alone. 
 
The treatment was aimed at normalizing the derangement of thodams and 
providing relief from symptoms. By giving purgation we can normalize the deranged 
Vatham. 
 
                                       
 
Before treatment the patients were advised to take Meganatha kuligai pills- 2nos 
with hot water in early morning for purgation. 
 
The patients were treated with trial drugs “Kandathri Chooranam” (internal) 
twice a day with hot water and “Erandai Ennai” (external) for 45 days. Patients were 
instructed to take the medicines regularly advised to follow pathiyam (avoid tamarind, 
tubers, etc) and advised to avoid cold exposure. 40 Patients were asked to visit the 
hospital once in 7 days and drugs were given for 45days and the clinical assessment was 
done on 1
st
 day, 12
th
 day, 24
th
 day, 36
th
 day and 45
th
 day. 
 
For Patients the drugs were given 1-45 days and the clinical assessment was done 
daily.  
After the treatment, for further follow up, patients were advised to visit the Out-
Patient ward of  Department of Sirappu Maruthuvam . 
 
CLINICAL MANIFESTATIONS: 
 
Pain in the knee joint was present in 40 cases. Swelling was Present in 13 cases. 
The other important features were morning stiffness in 3 cases, tenderness in 10 cases, 
restricted movements in 10 cases, crepitation were observed in 17 cases. 
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LABORATORY INVESTIGATIONS: 
 
 Laboratory investigations were done for all the cases before and after treatment. 
 There were no variations in hepatic, renal and other parameters. 
 The radiographic studies showed narrowed joint space and presence of 
 Osteophytes. The trial drug showed improvement in prognosis of the disease 
 clinically rather than in radiographic changes. 
 
EFFECT OF TREATMENT: 
 
Good improvement was observed in 25 (62.5%) Patients, moderate improvement 
in 4 (10%) and mild improvement in 8(20%). The mean pain score beforet and after 
treatment is Very Significant. 
 
Treatment status  t-value p-value Mean± Std deviation 
Before treatment 7 ± 1.076 0.0017 0.99 
After treatment 1.85±1.348 0.0027 0.0998 
 
EFFECT OF VARMAM: 
 
20  patients are treated with Varmam along with the trial drug. The results are 
compared at the end of the study. There is no significant difference between with and 
without varmam treatment groups before the start of treatment. The mean pain score 
before  and after treatment it was observed in Extremly Significant. Hence this study 
reveals the importance of Varmam therapy in the treatment of Osteoarthritis. 
 
Treatment status 
 
 t-value 
 
p-value 
 
Mean± Std deviation 
 
Before treatment 7.25±0.7864 0.0017 0.99  0.99 
After treatment 1.95±1.317 0.0027 0.0998 
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SUMMARY 
 
The clinical study on Azhal Keel Vayu with reference to its aetiology, 
pathogenesis, investigations, clinical features, diagnosis and treatment were conducted at 
the Sirappu Maruthuvam Department, Ayothidoss Pandithar Hospital, National Institute 
of Siddha, Chennai – 47. 
 
The drugs administered in the clinical study were used only after getting 
authentication from concern department and careful purification process. 
 
40 cases of both the sexes with the signs and symptoms of Azhal Keel Vayu were 
selected in the age group within 30 to 65 for the study. Out of 40patients, were 20 patients 
had treated under the varmam therapy along with the trial drugs. Rest of them 20 patients 
were treated  trial drug  alone.. 
 
All the details about the study and the drugs were informed to the patients in their 
vernacular language, dietary regimen and information sheet were given to them and 
signed consent forms were obtained from them. Before starting the treatment, the blood 
samples of the selected patients were subjected to investigation. 
 
On the first day of the treatment, purgation was given by administering 
Meganatha kuligai pills-2 nos with hot water in the early morning to normalize the 
deranged kuttram. 
From the second day onwards, the patients were treated with the trial drug 
“Kandathri Chooranam” 2gm bid with Cold water was given internally and “Erandai 
Thylam” externally. Every 8thday, the patients were assessed for clinical improvement 
and adverse effects. 
Before treatment (0th day) and at the end of the treatment (45th day) the 
laboratory investigations were done. The x-ray of the affected Joints were taken. The 
improvement was assessed. 
During the course of treatment there were no adverse effects or unwanted drug 
reactions in Gastro intestinal tract, Respiratory system, Cardio vascular system and 
excretory systems. 
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20  patients are treated with varmam along with the trial medicine. The results are 
compared at the end of the study. The mean pain score of the 20 patients who received 
varmam was reduced Hence varmam treatment along with trial medicine is effective in 
the treatment of Osteoarthritis. 
The study results showed that 62.5 % had Good improvement, 10 % had 
Moderate improvement and 20 % had mild improvement. The pain assessment was done 
in all the 40patients participated in the trial using the universal pain assessment scale and 
at the end of the study, the results showed, the mean pain score was reduced .  
 122 
 
CONCLUSION 
 
The study results showed that the efficacy of trial drug “Kandathri Chooranam” 
which is siddha herbal formulation.It was found to be good resulting on Azhal Keelvayu 
patients in reducing clinical symptoms like pain  ,swelling, restricted movements. 
 
Varmam treatment along with the trial drugs showed no significant prognosis 
when compared to patients treated only with trial drugs. Hence the study reveals the 
importance of Varmam in treating   Azhal Keel Vayu. 
 
Clinically, no adverse effects were reported during the trial and the laboratory 
investigations were also within normal limits. So, the drug is assumed to be safe for 
humans. 
 
Hence the study concludes that, the trial drugs are clinically effective in reduction 
of pain, swelling, restriction of movements. 
 
Because of the encouraging clinical results, it could be concluded that  
“Kandathri Chooranam” (Internally) and “Erandai thylam” (Externally) are effective 
in the treatment of  Azhal Keel Vayu (Osteoarthritis). 
 
However further work with large number of patients should be carried out towards 
finding the ideal dose response. 
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BIO-CHEMICAL ANALYSIS: Qualitative Analysis 
 
SL. NO EXPERIMENT OBSERVATION INFERENC
E 
1. Appearance of the sample Blackish Brown in 
Colour 
 
2. Solubility: 
a. A little of the sample is 
shaken well with distilled 
water. 
b. A little of the sample is 
Shaken well with con. Hcl 
Con. H2SO4. 
 
Sparingly soluble 
 
Sparingly soluble 
 
Presence of 
Silicate 
 
Preparation of the Extract 
 
2 gm of kandathri chooranam was weighed accurately and placed in a  250 ml 
clean beaker. Then 50 ml distilled water was added and dissolved well. Then it is boiled 
well for about 10 minutes. It was cooled and filtered in a 100 ml volumetric flask and 
then it was made up to 100 ml with distilled water. This fluid was taken for analysis. 
 
SL. 
NO.1 
EXPERIMENT OBSERVATION INFERENCE 
TEST FOR ACID RADICALS 
1. Test For Sulphate: 
a. 2 ml of the above prepared extract is 
taken in a test tube to this added 2ml of 4% 
ammonium oxalate solution. 
 
Cloudy appearance 
not present 
 
Absence of 
Sulphate. 
2. Test For Chloride: 
2 ml of the above prepared Extract is added 
with dil. HNO3 till the effervescence 
ceases. Then 2 ml of silver nitrate solution 
is added. 
 
Cloudy appearance 
present 
 
Presence of 
Chloride. 
3. Test For Phosphate: 
2 ml of the extract is treated with 2ml of 
ammonium molyb date solution and 2 ml 
of con. HNO3 
 
No Cloudy yellow 
appearance 
 
Absence of 
Phosphae. 
4. Test For Carbonate: 
2m1 of the extract is treated with 2m1 
magnesium sulphate 
Solution 
 
Cloudy 
appearance present 
 
Presence 
of 
Carbonate 
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 II. TEST FOR BASIC 
RADICALS 
  
 Test For Lead: 
2 m1of the extract is added with 
2m1of potassium iodide solution 
Yellow 
precipitate is 
obtained 
 
Presence 
of Lead. 
2. Test for Copper: 
a. One pinch of substance is made 
into paste with con. Hcl in a watch 
glass and introduced 
into the non-luminous part of the 
flame. 
b. 2 ml of extract is added with 
excess of ammonia solution. 
 
No Bluecolour 
flame 
precipitate 
 
 
No Bluecolour 
precipitate 
 
Absence of 
Copper. 
 
 
 
Absence of 
Copper. 
3. Test For Aluminium: 
Take the 2m1of the extract 
sodium hydroxide is added in 
drops to excess. 
 
characteristic 
changes 
 
Presence of 
Aluminium 
5. Test for fluoride & oxalate 
2 m1 of The Extract Is Added 
With 2m1of Acetic Acid and 2 m1 
calcium Chloride solution 
and heated. 
 
No Cloudy 
appearance. 
 
Absence of 
Fluoride & 
Oxalate 
 
6. 
Test for Nitrite: 
3drops of extract is placed on a 
filter paper,on that 2 drops of acetic 
Acid and 2 drops of benzidine 
solution is placed. 
 
 
No characteristic 
Changes. 
 
 
Absence of 
nitrite. 
 
7. 
Test For Borate: 
2 pinches of the substance is 
made into paste by using sulphuric 
acid and alcohol (95%) and 
introduced into the blue 
flame. 
 
Bluish green colour 
flame not appeared. 
 
Absence of 
borate. 
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4. Test For Iron: (Ferrous) 
To the 2 ml of extract 2m1 
ammonium thiocyanate solution 
and 2m1of con.HNO3 is added. 
 
Blood red colour 
Appearance 
 
 
Presence of Iron. 
5. Test For Zinc: 
To 2m1 of the extract sodium 
hydroxide solution is added in 
drops to excess. 
 
White precipitate is 
Formed 
 
Presence of Zinc. 
6. Test For Calcium: 
2m1 of the extract is added with 
2m1 of 4% ammonium oxalate 
Solution. 
Cloudy appearance 
and white precipitate 
is obtained 
 
Presence of 
Calcium. 
7. Test For Magnesium: 
To 2ml of extract sodium 
hydroxide solution is added in 
drops to excess. 
 
White precipitate is 
obtained. 
 
Presence of 
Magnesium 
8. Test For Ammonium: 
To 2ml of extract few ml of 
Nessler's reagent and excess of sodium 
hydroxide solution are added. 
 
Brown colour is 
appeared. 
 
Presence of 
Ammonium 
9. Test For Potassium: 
A pinch of substance is treated 
with 2ml of sodium nitrite solution 
and then treated with 2m1 of 
cobalt nitrate in 30% glacial 
acetic acid. 
 
No Yellowish 
precipitate is obtained 
 
Absence of 
Potassium. 
10. Test For Sodium: 
2 pinches of the substance is made 
into paste by using HCL and 
introduced into the blue 
flame of Bunsen burner. 
 
 
No Yellow colour 
Flame appeared. 
 
 
Absence of Sodium. 
11. Test For Mercury: 
2m1 of the extract is treated with 
2ml of sodium hydroxide solution. 
 
Yellow precipitate is  
obtained 
 
Presence of 
Mercury. 
 
12. 
Test For Arsenic: 
2m1 of the extract is treated with 
2m1 of sodium hydroxide solution. 
 
Brownish red 
Precipitate is obtained 
 
Presence of 
Arsenic. 
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III. MISCELLANEOUS 
1. Test for Starch: 
2ml of extract is treated with weak 
iodine solution. 
Blue colour 
developed 
Presence of 
Strarch. 
2. Test For Reducing Sugar: 
5. ml of Benedict's qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and 
added 8 to 10 drops of the extract 
and again boil it for 2 minutes. 
The colour changes are noted. 
 
Brick red colour 
developed 
 
Presence of 
Reducing 
sugar. 
3. Test For The Alkaloids: 
a. 2m1 of the extract is treated 
with 2ml of potassium Iodide 
solution. 
b. 2m1 of extract is treated with 
2ml of picric acid. 
c. 2m1 of the extract is treated with 
2ml of phosphotungstic acid. 
Red colour 
developed 
 
 Yellow colour 
developed 
White precipitate 
developed 
Presence of 
Alkaloid. 
 
Presence of 
Alkaloid. 
Presence of 
Alkaloid. 
4. Test for Tannic Acid: 
2ml of extract is treated with 
2ml of ferric chloride solution. 
Black precipitate 
is obtained 
Presence of 
Tannic acid. 
 
5. 
Test for Unsaturated 
Compound: 
To the 2ml of extract 2ml of 
Potassium Permanganate solution 
is added. 
Potassium 
Permanganate is 
decolourised 
Presence of 
Unsaturated 
Compound. 
6. Test For Amino Acid: 
2 drops of the extract is placed on 
a filter paper and dried well and 2 
ml of biuret reagent is added 
No Violet colour 
developed 
Absence of 
Amino acids. 
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RESULT: 
 
            The Bio-chemical analysis of Kandathri chooranam had shown the presence of 
Chloride,Carbonate, Lead, Aluminium, Iron, Zinc, Calcium, Magnesium, Ammonium, 
Mercury,Arsenic, Starch, Reducing Sugar, Alkaloids Unsaturated  Tannic acid, 
Compounds. 
7. Test For type of Compound: 
2ml of the extract is treated with 2 
ml of ferric chloride solution. 
 
 Green colour 
developed 
 
 
 
 
 
No Red colour 
developed 
 
 
 
 
No Violet 
colour 
developed 
 
 
 
 
No blue 
colour 
developed 
 
Presence of 
oxy quinole 
epinephrine 
and pyro 
catechol. 
 
Anti pyrine, 
Aliphatic 
amino acids 
and Meconic 
acid are absent. 
 
Apomorphin
e, Salicylate 
and 
Resorcinol 
are absent. 
 
Morphine, 
Phenol 
cresol and 
hydro quinone 
are 
absent 
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                                               NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
 
COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG “KANDATHIRI 
CHOORANAM” (INTERNAL) AND “ERANDAI THAILAM” (EXTERNAL) IN THE 
TREATMENT OF   “AZHAL KEEL VAYU” (OSTEOARTHRITIS OF KNEE JOINT) 
WITH AND WITHOUT VARMAM THERAPY. 
Principal Investigator: Dr.V.Rubini                                                              
FORM I - SCREENING & SELECTION PROFORMA 
 
1. SERIAL NO:      2. OP /IP NO:                              
3. NAME:            4. AGE/GENDER:    
5. OCCUPATION:           6. INCOME:  
 
INCLUSION CRITERIA 
 Whether age is between 30-65                                  YES\ NO  
 Sex                            M \ F 
 Pain & Swelling of both knee joints.                YES\ NO  
 Crepitations                                                                   YES\ NO  
 Stiffness & Restricted movements                                                     YES\ NO  
 Willing to attend OPD or admission in IPD for the trial   YES\ NO 
 Willingness for consent       YES\ NO 
 Willing to give specimen of blood for the investigation     YES\ NO 
 Willing to undergo radiological investigation                            YES\ NO 
 
EXCLUSION CRITERIA 
 Cardiac disease        YES\ NO  
 Rheumatoid arthritis       YES\ NO 
 Tuberculosis of knee       YES\ NO 
 Septic arthritis        YES\ NO 
 Gonococcal arthritis       YES\ NO 
 Pregnancy and lactation      YES\ NO 
 Chronic kidney disease      YES\ NO 
 Patient with any other serious systemic illness   YES\ NO 
 H/O diabetes mellitus       YES\NO 
 
ADMITTED TO TRAIL 
YES  NO  
If Yes, OPD  IPD  
  Serial NO:  
Date:        
Station:      
Signature of the Investigator:  
Signature of the Lecturer:                                                           Signature of the HOD 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG “KANDATHIRI CHOORANAM” 
(INTERNAL) AND “ERANDAI THAILAM” (EXTERNAL) IN THE TREATMENT OF   “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS OF KNEE JOINT) WITH AND WITHOUT VARMAM 
THERAPY. 
Principal Investigator: Dr.V.Rubini                                                              
 
STUDY  NO:   OP / IP NO: 
NAME: AGE / GENDER: 
ADDRESS: CONTACT NO : 
 RELIGION :  H / C / M / O. 
OCCUPATION: INCOME: 
MARITAL STATUS :       1. Married 2. Unmarried 
DATE OF INTIAL ASSESSMENT:  
COMPLAINTS & DURATION:   
FORM II-A – HISTORY TAKING PROFORMA 
                                                                                                                                                                                
PERSONAL HISTORY: 
PERSONAL HABITS YES NO 
IF YES 
SPECIFY 
DURATION 
AMOUNT/Qty 
Smoking     
Tobacco Chewing     
Alcohol     
Narcotic  Drug Addiction     
  
HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
 
FAMILY HISTORY:  
Whether this problem runs in family? 1. Yes            2. No    
If yes, mention the relationship of affected 
person(s) 
1._________________ 
 
2._________________ 
 
DIETARY STYLE: 1. Vegetarian    2. Non-vegetarian 
 
 
MENSTURAL AND OBSTETRIC HISTORY: 
 
                                                                                       
 
 
 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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                                                      FORM –II B 
 
GENERAL EXAMINATION: 
1. Body weight [Kg]    :                      
2. Height [cms]                       :                        
3. Body Temperature [F]       :   
4. Blood Pressure (mm/Hg)  :      
5. Pulse Rate /min.        : 
6. Heart Rate / min.         : 
7. Respiratory Rate /min.  :   
                                                                                  Yes            No   
8. Pallor   :   
9. Jaundice   :   
10. Clubbing   : 
11. Cyanosis   : 
12. Pedal Oedema   : 
13. Lymphadenopathy            :                                        
14. Jugular venous pulsation   :   
SYSTEMIC EXAMINATION 
  Cardiovascular system  :  
  Respiratory system   :  
  Gastro-intestinal system  :  
  Central Nervous system  :  
  Urogenital system   :  
  Endocrine system              :  
SIDDHA SYSTEM OF EXAMINATION 
1. THEGI (BODY CONSTITUTION): 
1. Vatha udal 
2. Pitha udal 
3. Kaba udal 
4. Thontha udal 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji (Hilly terrain) 
2. Mullai (Forest range) 
3. Marutham (Plains) 
4. Neithal (Coastal belt) 
5. Paalai (Aridregion) 
3. KAALAM: 
1. Kaar kaalam    (Aavani-Purattasi) 
2. Koothir kaalam     (Ippasi-Kaarthigai) 
3. Munpani kaalam     (Maargazhi-Thai) 
4. Pinpani kaalam       (Maasi-Panguni) 
5. Ilavenil kaalam        (Chithirai-Vaigasi) 
6. Muthuvenil kaalam (Aani-Aadi) 
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4. GUNAM: 
1. Sathuvam  
2. Rasatham 
3. Thamasam 
 
5. PORIPULANGAL (SENSORY ORGANS):          
                  
  
 
 
 
 
 
 
 
6.KANMENDRIYAM (MOTOR ORGANS) : 
        
 
 
 
 
 
 
 
7.KOSANGAL (SHEATH):                
 
 
 
 
 
 
  
   
 
 
8. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
 Before treatment After treatment 
Saaram Normal  /Affected Normal  /Affected 
Senneer  Normal  /Affected Normal  /Affected 
Oon Normal  /Affected Normal  /Affected 
Kozhuppu Normal  /Affected Normal  /Affected 
Enbu Normal  /Affected Normal  /Affected 
Moolai Normal  /Affected Normal  /Affected 
Sukkilam / Suronitham Normal  /Affected Normal  /Affected 
 Before treatment After treatment 
Mei (Skin) Normal  / Affected Normal  / Affected 
Vai (Tongue) Normal  / Affected Normal  / Affected 
Kann (Eye) Normal  / Affected Normal  / Affected 
Mooku (Nose) Normal  / Affected Normal  / Affected 
Sevi (Ear) Normal  / Affected Normal  / Affected 
 Before treatment After treatment 
Kai(Upper limb) Normal  /Affected Normal  /Affected 
Kaal (Lower limb) Normal  /Affected Normal  /Affected 
Vai (Oral cavity)   Normal  /Affected Normal  /Affected 
Eruvai (Anal reg.) Normal  /Affected Normal  /Affected 
Karuvai (Uro-
genital region) 
Normal  /Affected Normal  /Affected 
 Before treatment After treatment 
Annamaya kosam Normal  /Affected Normal  /Affected 
Pranamaya kosam  Normal  /Affected Normal  /Affected 
Manomaya kosam  Normal  /Affected Normal  /Affected 
Vignanamaya kosam  Normal  /Affected Normal  /Affected 
Ananthamaya kosam Normal  /Affected Normal  /Affected 
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9. UYIR THAATHUKKAL: [THREE HUMORS] (VALI/ AZHAL/ IYYAM) 
 
A) VALI 
 
 0
th
 day 8
th
 day 15
th
 day 22
nd
 day 29
th
 day 36
th
 day 43
rd
 day 49
th
 day 
Praanan         
Abaanan         
Samaanan         
Udhaanan         
Viyaanan         
Naagan         
Koorman         
Kirukaran         
Devathathan         
Dhananjeyan         
 
 
B) AZHAL 
 
 0
th
 day 8
th
 day 15
th
 day 22
nd
 day 29
th
 day 36
th
 day 43
rd
 day 49
th
 day 
Analakam         
Ranjakam          
Saathakam          
Prasakam          
Aalosakam         
 
 
136 
 
 
 
C) IYYAM 
 
 0
th
 day 8
th
 day 15
th
 day 22
nd
 day 29
th
 day 36
th
 day 43
rd
 day 49
th
 day 
Avalambagam         
Kilethagam         
Pothagam         
Tharpagam         
Santhigam         
 
 
10. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION] 
 
I. NAADI: [PULSE PERCEPTION] 
 
NAADI 0
th
  day 8
th 
day
 
15
th 
day 22
nd
day 29
th
day 36
th
  day 43
rd
day 49
th
day 
         
 
II. SPARISAM: [PALPATION] 
 
Day SPARISAM 
0
th
  day  
8
th 
day
  
15
th
  day  
22
nd
  day  
29
th
  day  
36
th
  day  
43
rd
 day  
49
th 
day  
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III. NAA: [TONGUE] 
 
NAA 0
th
day 8
th
day
 
15
th
day 22
nd
day 29
th
day 36
th
day 43
rd
day 49
th
day 
         
 
 
 
IV. NIRAM: [COMPLEXION]   
    1. Vadham         
     2. Pitham 
      3. Kabam  
 
 
 
V. MOZHI: [VOICE] 
      1. High Pitched 
      2. Low Pitched 
      3. Medium Pitched 
 
 
 
VI.VIZHI: [EYES] 
VIZHI 0
th
  day 8
th 
day
 
15
th
day 22
nd
day 29
th
day 36
th
  day 43
rd
day 49
th
day 
         
 
 
 
VII. MALAM: [BOWEL HABITS / STOOLS] 
 Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
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VIII. MOOTHIRAM [URINE EXAMINATION]  
NEERKKURI: 
Neerkkuri Before treatment After treatment 
Niram   
Manam   
Edai   
Nurai   
Enjal   
 
 
 
NEIKKURI:  
 
Neikkuri Before treatment After treatment 
 Aravana needathu/ 
Snake like pattern 
 
  
Azhipol paraviyathu 
Annular/Ringedpattern 
 
 
 
parav paraparavoiyadu 
  
Muththothu ninrathu  
Pearlbeadepattern 
  
Other patterns   
 
 
 
CLINICAL EXAMINATION:        
           
LOCOMOTOR SYSTEM: 
 CLINICAL SYMPTOMS: 
Affected knee joints: Right Left    Both               
Pain in knee joint: Mild Moderate   Severe 
Onset:                             Sudden                   Gradual 
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CLINICAL EXAMINATION OF KNEE JOINT   
I.INSPECTION: 
 0
th
 day 8
th
 day 15
th
 day 22
nd
day 29
th
 day 36
th
 day 43
rd
day 49
th
 day 
Attitude:         
swelling         
Skin over the 
knee joints 
        
Muscle 
wasting 
        
Deformity 
 
        
 
II.PALPATION: 
 0
th
 day 8
th
 day 15
th
 day 22
th
 day 29
th
 day 36
th
 day 43
rd
day 49
th
 day 
Tenderness         
Crepitation         
Local heat         
 
III. MOVEMENTS 
 0
th
 day 8
th
 day 15
th
 day 22
nd
day 29
th
 day 36
th
 day 43
rd
day 49
th
 day 
Flexion         
Extension         
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IV. JOINT MESUREMENT: 
A. HEALTH ASSESSMENT QUESTIONNAIRE: 
 
 0
th
 day 8
th
 day 15
th
 day 22
nd
day 29
th
 day 36
th
 day 43
rd
day 49
th
 day 
PAIN 
A. Onset: 
Sudden/Gradual 
        
B. Early morning  
Stiffness 
(Present/absent) 
        
C. Nature of pain                                             
(Mild/ Moderate/ 
Severe) 
        
D. Aggravating   
factor- 
Movement  
(Yes/No) 
        
E. Relieving factor 
–Rest 
(Yes/No) 
        
G. Tenderness 
(Present/absent) 
        
RESTRICTION 
OF MOVEMENT  
(Fully/Partial/No) 
Knee joints 
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A. UNIVERSAL PAIN ASSESMENT SCALE:
 
 
  Grade   0    :  No Pain 
  Grade 1 -3 :   Mild pain 
  Grade 4-6 :   Moderate pain 
             Grade 7-10 :   Severe pain     
 
 
B. RESTRICTED MOVEMENT ASSESSMENT SCALE:  
Grade 1 - Fit for all activities, do their work without support. 
 Grade II - Mild pain present in knee joint, mild restricted movements. Grade III - 
Pain present in knee joint, moderate restriction of movements. Grade IV - Severe pain, 
bed ridden. 
(Ref: Clinical manual for nursing practice (National Institute of Health Warren Grant 
Magnuson Clinical Centre 
 
 
C .Questionnaire of  Osteoarthritis : 
 
Name 
Age 
   
Which knee is bothering you?  
 
Right    Left    Both 
Did your knee pain start with a specific injury?  
 
Yes   No 
If yes: Date of injury:  
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Mechanism of injury : 
 
 
Did you feel a pop or snap with the injury?  
 
Yes       No 
Is the injury work related? 
 
 Yes   No 
Did your pain start with a particular sport or activity? 
  
Yes   No 
If yes, what started the pain?  
 
If there was no injury, when did the pain start?  
 
 
What part of your knee hurts? Front Inside Outside Back 
What are your primary sports and/or activities?  
 
How would you describe your pain? (constant, intermittent, mild, severe, etc.) 
 
Do any of the following increase your pain? 
 
Prolonged walking: Yes  Minimally  No 
 
Prolonged standing: Yes   Minimally    No 
 
Going up or down stairs:  Yes  Minimally  No 
 
Prolonged sitting: Yes  Minimally  No 
Getting up from a sitting position:  Yes  Minimally  No 
 
Kneeling or squatting: Yes  Minimally  No 
 
Pivoting or twisting motions:  Yes  Minimally  No 
 
Running:  Yes  Minimally  No 
 
Sports:  Yes  Minimally  No 
 
Is there anything else that increases your pain?  
 
Do any of the following decrease your pain? 
 
Rest:  Yes  Minimally  No 
 
Ice:  Yes  Minimally  No 
 
Heat:  Yes  Minimally  No 
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Do you have any of the following symptoms? 
Weakness in your leg:  Yes  Minimally  No 
 
Giving way or buckling of your knee:  Yes  Minimally  No 
 
Locking of your knee (unable to fully straighten):  Yes  Minimally  No 
 
Clicking or catching in your knee:  Yes  Minimally  No 
 
Grinding sensation in your knee:  Yes  Minimally  No 
 
Swelling of your knee:  Yes  Minimally  No 
 
Stiffness:  Yes  Minimally  No 
 
Pain at night:  Yes  Minimally  No 
 
Numbness or tingling in your leg:  Yes  Minimally  No 
 
Are there any other symptoms that we need to know about regarding your knee? 
Have you had any prior surgery to your knee(s)?  Yes  No 
 
If yes, what type of surgery did you have and when did you have the surgery? 
 
Have you had any prior treatment for your knee pain such as: 
 
Cortisone injections:  Yes  No 
 
Synvisc, Euflexxa or “Gel” injections:  Yes  No 
 
Physical therapy:  Yes  No 
 
Do you use any ambulatory aids (cane, crutches, walker)  Yes  No 
 
Have you had any x-rays taken of your knee(s):  Yes  No 
 
If yes: Date of x-rays: 
 
X-ray facility 
 
Have you had an MRI of your knee(s):  Yes  No 
 
If yes: Date of MRI:  
Is there anything else we need to know about your knee pain? 
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 FORM II-C-VARMAM ASSESSMENT FORM 
VARMAM POINTS TO BE APPLIED TO THE PATIENT: 
 Kaal Mootu Varmam (Varma Viralalavu Nool) 
 Komberi (Varma soothiram 101) 
 Viruthi (Varma laada soothiram 300) 
 Ullangal Vellai(Adivarma sootcham 500 
 
Day Date Varmam Day Date Varmam 
Day 1   Day25   
Day2   Day26   
Day3   Day27   
Day4   Day28   
Day5   Day29   
Day6   Day30   
Day7   Day31   
Day8   Day32   
Day9   Day33   
Day10   Day34   
Day11   Day35   
Day12   Day36   
Day13   Day37   
Day14   Day38   
Day15   Day39   
Day 16   Day 40   
Day 17   Day 41   
Day 18   Day 42   
Day 19   Day43   
Day 20    Day 44   
Day 21    Day 45   
Day 22   Day 46   
Day 23   Day 47   
Day 24   Day 48   
                                                                                 
Date:          
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                           Signature of the HOD 
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HOORANAM” (INTERNAL) AND “ERANDAI THAILAM” (EXTERNAL) IN THE 
TREATMENT OF   “AZHAL KEEL VAYU” (OSTEOARTHRITIS OF KNEE JOINT) 
WITH AND WITHOUT VARMAM THERAPY. 
Principal Investigator: Dr.V.Rubini 
 
1. SERIAL NO:      2. OP /IP NO:                              
3. NAME:            4. AGE/GENDER: 
 
FORM -III - LABORATORY INVESTIGATIONS 
 
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb( gm/dl) 
M:13-18 
W:11-16 
  
T.RBC(millions cells /Cu.mm) 
M:4.5-6.5 
W:3.5-5.5 
  
ESR (mm) 
½ hr. -   
1 hr. 
M:0-10 
W:0-20 
  
T.WBC (Cells /Cu.mm) 4000-11000   
Differential 
Count (%) 
Polymorphs 40-75   
Lymphocytes 20-35   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
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BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Blood 
glucose 
(mg/dl) 
Fasting 70-110   
PP 80-140   
Lipid 
profile 
(mg/dl) 
Serum cholesterol 150-200   
HDL 30-60   
LDL Up to 130   
VLDL 40   
TGL Up to 160   
RFT 
(mg/dl) 
Blood urea 16-50   
Serum creatinine 0.6-1.2   
LFT 
(mg/dl) 
Total bilirubin 0.2-1.2   
Direct bilirubin 0.1-0.2   
Indirect bilirubin 0.2-0.7   
Total protein 6-8   
Serum Albumin 3.5-5.5   
Serum globulin 2-3.5   
SGOT (IU/L) 0-40   
SGPT (IU/L) 0-35   
Alkaline phosphatase 
(IU/L) 
80-290   
 
Serum calcium 9-11   
Serum phosphorus 2-5   
Serum Uric acid 
M:3-9 
W: 2.5-7.5 
  
 CRP   
 ASO titre   
 RA factor   
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B.URINE INVESTIGATIONS: 
 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT 
AFTER 
TREATMENT 
Albumin   
Sugar (Fasting) 
        (PP) 
  
Deposits   
Bile salts   
Bile pigments   
 
  
 
C.RADIOLOGICAL EXAMINATIONS 
X- Ray: Knee joint: 
1. Antero posterior  
2. Lateral view 
 
 
Date:          
 
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                           Signature of the HOD 
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COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG “KANDATHIRI CHOORANAM” 
(INTERNAL) AND “ERANADAI THAILAM” (EXTERNAL) IN THE TREATMENT OF   “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS OF KNEE JOINT) WITH AND WITHOUT VARMAM THERAPY. 
Principal Investigator: Dr.V.Rubini 
  
FORM  - IV (DRUG COMPLIANCE FORM) 
 
On 1
st    
 day-Date:  Drugs issued:     (Gram)     Drugs returned:    (Gram) 
On 8
th
   day-Date:   Drugs issued:     (Gram)     Drugs returned:    (Gram) 
On 15
th
 day-Date:              Drugs issued:     (Gram)     Drugs returned:    (Gram) 
On 22
th
 day-Date:           Drugs issued:     (Gram)     Drugs returned:    (Gram) 
On 29
th
 day-Date:             Drugs issued:     (Gram)     Drugs returned:    (Gram) 
On 36
th
 day-Date:              Drugs issued:     (Gram)     Drugs returned:    (Gram) 
On 43
th
 day-Date:                Drugs issued:     (Gram)     Drugs returned:    (Gram) 
Date: 
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the 
   DEPARTMENT OF SIRAPPU MARUTHUVAM 
SERIAL NO:                                         OP/IP NO: 
NAME:                                              
AGE/GENDER: 
DRUGNAME:SAGALAVATHACHOORANAM 
Day Date Morning Evening Day Date Morning Evening 
Day 1    Day6    
Day2    Day7    
Day3    Day8    
Day4    Day9    
Day5    Day10    
Day11    Day30    
Day12    Day31    
Day13    Day32    
Day14    Day33    
Day15    Day34    
Day16    Day35    
Day17    Day36    
Day18    Day37    
Day19    Day38    
Day20    Day39    
Day21    Day40    
Day22    Day41    
Day23    Day42    
Day24    Day43    
Day25    Day44    
Day26    Day45    
Day27        
Day28        
Day29        
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KEEL VAYU” (OSTEOARTHRITIS OF KNEE JOINT) WITH AND WITHOUT VARMAM THERAPY. 
FORM V – PATIENT INFORMATION SHEET 
Name of Principal Investigator: Dr.V.Rubini      
 
Name of the institute: National Institute of Siddha, 
                                      Tambaram Sanatorium, 
                                      Chennai-47. 
 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
 
I Dr.V.Rubini Studying M.D (Siddha) at National Institute of Siddha, Tambaram 
Sanatorium is doing a trial on AZHALKEEL VAYU (OSTEOARTHRITIS). Osteo arthritis 
is a most common degenarative disease, occurring throughout the world. In this regard, I 
am in a need to ask you few questions. I will maintain confidentiality of your comments 
and data obtained. There will be no risk of disclosing your identity and no physical, 
psychological or professional risk is involved by taking part in this study. Taking part in 
this study is voluntary. No compensation will be paid to you for taking part in this study. 
 
           You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in 
the study may be of benefit to the community, as it may help us to understand the 
problem of defaulters and potential solutions. 
 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
KANDATHIRI CHOORANAM (Internal medicine- 1.5gm BD with hot water for 45days) 
and ERANDAI THAILAM(External medicine), if you wish to stay in the 
 In Patient ward VARMAM Treatment will be provided to you assuring that you will not 
be definitely hurt in any course of treatment. 
 
  The information I am collecting in this study will remain confidential. I will ask 
you few questions through a questionnaire.  
 
If you wish to find out more about this study before taking part, you can ask me 
all the questions you want or contact Dr.V.Rubini PG Scholar, Ph.no:8939562365 cum 
principal investigator of this study, attached to National Institute of Siddha, Chennai-47. 
You can also contact the Member-secretary of Ethics committee, National Institute 
Siddha, Chennai 600047, for rights and participation in the study. 
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¾¸Åø  ÀÊÅõ 
 
«Æø¸£ø Å¡Ô  §¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸Ç¢ý ¸ñ¼¡ò¾¢Ã¢ ÝÃ½õ 
(¯û ÁÕóÐ) ÁüÚõ  ²Ãñ¨¼ò ¨¾Äõ  (¦ÅÇ¢ ÁÕóÐ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì                 
¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷     :  ÁÕ. Å£.åÀ¢É¢ 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷              :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
                                    ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
                                        ¦ºý¨É- 47 
 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý 
(ÁÕòÐÅ÷ ÁÕ. Å£.åÀ¢É¢) «Æø¸£ø Å¡Ô ±ýÛõ  §¿¡öì¸¡É ÁÕòÐÅ 
¬Ã¡öîº¢Â¢ø ®ÎÀðÎû§Çý.               
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Çì §¸ð¸×õ, §¾¨ÅÂ¡É ¬öÅ¸ 
ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý. 
 
þó¾ ¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø ¯ûÁÕó¾¡¸ 
¸ñ¼¡ò¾¢Ã¢ ÝÃ½õ 1.5 ¸¢Ã¡õ ¦Åó¿£Ã¢ø 2 §Å¨Ç  (¸¡¨Ä Á¡¨Ä) ¯½×ìÌô 
À¢ý 48 ¿¡ð¸ÙìÌ ¯ð¦¸¡ûÇ §ÅñÎõ. ¦ÅÇ¢ ÁÕó¾¡¸ ²Ãñ¨¼ò ¨¾Äõ 48 
¿¡ð¸ÙìÌ §¿¡ÔûÇ þ¼í¸Ç¢ø ¦ÅÇ¢§Â ¾¼Å §ÅñÎõ. ¦ÅÇ¢ §¿¡Â¡Ç÷ 7 
¿¡ð¸ÙìÌ ´ÕÓ¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. ¯û §¿¡Â¡Ç¢Â¡¸ ¾í¸ 
Å¢ÕôÀõ ¦¾Ã¢Å¢ìÌõ Àðºò¾¢ø §¿¡öìÌò ¾Ìó¾ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. 
 
þÐ ºõÀó¾Á¡É ¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ ±É ¯Ú¾¢ 
«Ç¢ì¸¢§Èý. þ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ ¦¾¡¨¸Ôõ ÅÆí¸ôÀ¼ Á¡ð¼¡Ð. 
 þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ Á¡üÚ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. þó¾ ¬Ã¡öîº¢Â¢ø ¾í¸¨Ç 
¯ðÀÎò¾¢Â À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀÁ¢ø¨Ä¦ÂÉ¢ø ±ô§À¡Ð §ÅñÎÁ¡É¡Öõ 
Å¢Ä¸¢ ¦¸¡ûÇ ÓØ ¯Ã¢¨Á ¯ûÇÐ. 
 
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ ÁüÈ Å¢ÀÃí¸ÙìÌõ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ  
Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ÁÕ. Å£.åÀ¢É¢ (Àð¼ §Áü ÀÊôÀ¡Ç÷ º¢ÈôÒ ÁÕòÐÅ 
À¢Ã¢×) «Ï¸×õ. ¨¸ô§Àº¢ ±ñ 8939562365 §ÁÖõ þó¾ ¬Ã¡öîº¢ìÌ IEC º¡ýÚ 
¦ÀÈôÀðÎûÇÐ. 
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KEEL VAYU” (OSTEOARTHRITIS OF KNEE JOINT) WITH AND WITHOUT VARMAM 
THERAPY. 
Principal Investigator: Dr.V.Rubini 
                                                            
CONSENT FORM    -   FORM  
 
“I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction.  
            I consent voluntarily to participate as a participant in this study and 
understand that I have the   right to withdraw from the study at any time without in 
any way it affecting my further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
Date:  
Signature of the participant 
In case of illiterate participant 
 
        “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
individual has given consent freely.”                                                   
 
 
Date: 
 
 
 
Signature of a witness  
(Selected by the participant bearing no connection with the survey team)  
        
          
            
 
 
Left thumb Impression of the Participant 
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CHOORANAM” (INTERNAL) AND “ERANADAI THAILAM” (EXTERNAL) IN 
THE TREATMENT OF   “AZHAL KEEl VAYU” (OSTEOARTHRITIS OF KNEE 
JOINT) WITH AND WITHOUT VARMAM THERAPY. 
Principal Investigator: Dr.V.Rubini 
                                                           
FORM VII - WITHDRAWAL FORM 
 
1. SERIAL NO OF THE CASE: …………………   
2. OP / IP NO: ......................................    
3. NAME: ………………………     
4.AGE: …………        
5.GENDER:...........                           
6. DATE OF TRIAL COMMENCEMENT: ………………... 
7. DATE OF WITHDRAWAL FROM TRIAL: …………….. 
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:               Yes/ No 
Irregular treatment:                           Yes/ No 
Shift of locality:                                     Yes/No 
Increase in severity of symptoms:     Yes/No 
Development of severe adverse drug reactions:   Yes/No 
Development of adverse event:                                             Yes/No 
(If YES, give the details of adverse reaction in Form VII -B – Adverse 
Reaction Form / Pharmaco Vigilance Form) 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                          Signature of the HOD 
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COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG “KANDATHIRI 
CHOORANAM” (INTERNAL) AND “ERANDAI THAILAM” (EXTERNAL) IN THE 
TREATMENT OF   “AZHAL KEEL VAYU” (OSTEOARTHRITIS OF KNEE JOINT) 
WITH AND WITHOUT VARMAM THERAPY. 
Principal Investigator: Dr.V.Rubini  
                                                             
FORM  - VIII  DIETARY ADVICE FORM 
 
§º÷ì¸ ÜÊÂ ¯½×¸û ¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û 
¸¡ö¸û (Vegetables): 
¸ò¾Ã¢ôÀ¢ïÍ (Unripe brinjal) 
ÓÕí¨¸ôÀ¢ïÍ (Unripe drumstick) 
«Å¨ÃôÀ¢ïÍ (Unripe Dolichos bean) 
¸£¨Ã¸û(Greens): 
¦À¡ýÉ¡í¸ñ½¢ (Sessile plant 
[Alternanthera sessilis] ) 
ãì¸¢Ãð¨¼ (Hog weed [Boerhaavia diffusa] ) 
àÐ§Å¨Ç (Climbing brinjal [Solanum 
trilobatum] ) 
ÓÕí¨¸ì¸£¨Ã (Leaves of Drumstick 
[Moringa oleifera] ) 
¸È¢§ÅôÀ¢¨Ä (Curry leaf [Murraya koenigii] ) 
Ó¼ì¸Úò¾¡ý (Winter cherry [Cardiospermum 
halicacabum] ) 
«Ú¸£¨Ã (Amaranthus tristis) 
¸Ã¢º¡¨Ä (trailing eclipta [Eclipta prostrate] ) 
ÀÆí¸û(Fruits): 
Á¡Ð¨Ç (Pomegranate) 
¬ôÀ¢û (Apple)/ ÀôÀ¡Ç¢ (Papaya) 
¬ÃïÍ (Orange)/ §ÀÃ£î¨º (Dates) 
«ò¾¢ (Fig) 
¿¡Åø (Jambul [Syzygium cumini] ) «¨ºÅõ 
(Non-vegetarian diet): 
¦ÅûÇ¡ðÎì¸È¢ (Meat)  
¸¡¨¼ (Quail), þÈ¡øÁ£ý (Prawn) 
Í¨Ã (Bottle gourd) 
âº½¢ (Pumpkin) 
¦ÅûÇÃ¢ì¸¡ö (Cucumber) 
Ò¼¨Ä (Snake gourd) 
À£÷ìÌ (Ridged gourd) 
¯ÙóÐ (Black gram) 
¦Á¡î¨º (Indian butter Bean) 
¸¡Ã¡Á½¢ (Cow gram) 
¦¸¡ûÙ (Horse gram) 
¸ÎÌ (Mustard) 
±ñ¦½ö (Gingelly oil) 
ÒÇ¢ôÒ (Sour) 
¯ôÒ (Salt) 
Å¡Ôô ¦À¡Õð¸û (Vatha diet) 
¯Õ¨Çì ¸¢ÆíÌ (Potato) 
Å¡¨Æì ¸¡ö (Plantain) 
Ò¨¸Â¢¨Ä (Tobacco) 
ÁÐ «ÕóÐ¾ø (Alcohol) 
¦Àñ§À¡¸õ (þîº¡ Àò¾¢Âõ) [Sexual 
intercourse] 
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 ÁÕòÐÅ «È¢×¨Ã: 
 
®ÃÁ¢øÄ¡ò ¾¨ÃÂ¢Öõ, ÀÎì¨¸Â¢Öõ ÀÎò¾ø §ÅñÎõ,  ÌÇ¢÷ ¸¡üÚ ÀÎõÀÊÂ¡É 
þ¼ò¾¢ø þÕôÀ¨¾ò ¾Å¢÷ì¸×õ. ¯¼ø «¾¢¸ ±¨¼ þÕôÀ¢ý ±¨¼¨Âì 
Ì¨Èì¸ §ÅñÎõ. «¾¢¸ àÃõ ¿¼ò¾ø, «¾¢¸ §¿Ãõ ¿¢üÈø ¾Å¢÷ì¸×õ 
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FORM –IX ADVERSE REACTION FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                             AGE:                     GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF THE ADVERSE REACTION OCCUR: 
DESCRIPTION OF ADVERSE REACTION: 
 
 
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                            Signature of the HOD 
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